

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|   |           |   |
|---|-----------|---|
| <b>(51) International Patent Classification <sup>6</sup> :</b><br><b>C12N 15/86, A61K 48/00</b>   | <b>A1</b> | <b>(11) International Publication Number:</b> <b>WO 98/22609</b><br><b>(43) International Publication Date:</b> 28 May 1998 (28.05.98)  |
| <b>(21) International Application Number:</b> PCT/US97/21494<br><b>(22) International Filing Date:</b> 20 November 1997 (20.11.97)<br><br><b>(30) Priority Data:</b><br>08/752,760 20 November 1996 (20.11.96) US<br><br><b>(71) Applicant (for all designated States except US):</b> GENZYME CORPORATION [US/US]; One Mountain Road, Framingham, MA 01701 (US).<br><br><b>(72) Inventors; and</b><br><b>(75) Inventors/Applicants (for US only):</b> ARMENTANO, Donna, E. [US/US]; 352 Brighon Street, Belmont, MA 02178 (US). GREGORY, Richard, J. [US/US]; 2 Wintergreen Lane, Westford, MA 01866 (US). SMITH, Alan, E. [GB/US]; 1 Mill Street, Dover, MA 02030 (US).<br><br><b>(74) Agent:</b> SEIDE, Rochelle, K.; Baker & Botts, LLP, 30 Rockefeller Plaza, New York, NY 10112 (US).                                    |           | <b>(81) Designated States:</b> AU, CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).<br><br><b>Published</b><br><i>With international search report.<br/>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> |
| <b>(54) Title:</b> CHIMERIC ADENOVIRAL VECTORS<br><br><b>(57) Abstract</b><br><br>A chimeric adenoviral vector is provided that comprises nucleotide sequence of a first adenovirus, wherein all or part of at least one gene of said first adenovirus encoding a protein that facilitates binding of said vector to a target mammalian cell, or internalization thereof within said cell, is replaced by all or part of the corresponding gene from a second adenovirus belonging to subgroup D, said vector further comprising a transgene operably linked to a eucaryotic promoter to allow for expression therefrom in a mammalian cell. Compositions comprising such vectors and methods of using such vectors to deliver transgenes to target mammalian cells, particularly airway epithelial cells, are also provided. |           |   |

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |  |    |  |    |                          |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania                  | ES | Spain                                    | LS | Lesotho                                      | SI | Slovenia                 |
| AM | Armenia                  | FI | Finland                                  | LT | Lithuania                                    | SK | Slovakia                 |
| AT | Austria                  | FR | France                                   | LU | Luxembourg                                   | SN | Senegal                  |
| AU | Australia                | GA | Gabon                                    | LV | Latvia                                       | SZ | Swaziland                |
| AZ | Azerbaijan               | GB | United Kingdom                           | MC | Monaco                                       | TD | Chad                     |
| BA | Bosnia and Herzegovina   | GE | Georgia                                  | MD | Republic of Moldova                          | TG | Togo                     |
| BB | Barbados                 | GH | Ghana                                    | MG | Madagascar                                   | TJ | Tajikistan               |
| BE | Belgium                  | GN | Guinea                                   | MK | The former Yugoslav<br>Republic of Macedonia | TM | Turkmenistan             |
| BF | Burkina Faso             | GR | Greece                                   |    |  | TR | Turkey                   |
| BG | Bulgaria                 | HU | Hungary                                  | ML | Mali   | TT | Trinidad and Tobago      |
| BJ | Benin                    | IE | Ireland                                  | MN | Mongolia                                     | UA | Ukraine                  |
| BR | Brazil                   | IL | Israel                                   | MR | Mauritania                                   | UG | Uganda                   |
| BY | Belarus                  | IS | Iceland                                  | MW | Malawi                                       | US | United States of America |
| CA | Canada                   | IT | Italy                                    | MX | Mexico                                       | UZ | Uzbekistan               |
| CF | Central African Republic | JP | Japan                                    | NE | Niger  | VN | Viet Nam                 |
| CG | Congo                    | KE | Kenya                                    | NL | Netherlands                                  | YU | Yugoslavia               |
| CH | Switzerland              | KG | Kyrgyzstan                               | NO | Norway                                       | ZW | Zimbabwe                 |
| CI | Côte d'Ivoire            | KP | Democratic People's<br>Republic of Korea | NZ | New Zealand                                  |    |                          |
| CM | Cameroon                 |    |  | PL | Poland                                       |    |                          |
| CN | China                    | KR | Republic of Korea                        | PT | Portugal                                     |    |                          |
| CU | Cuba                     | KZ | Kazakhstan                               | RO | Romania                                      |    |                          |
| CZ | Czech Republic           | LC | Saint Lucia                              | RU | Russian Federation                           |    |                          |
| DE | Germany                  | LI | Liechtenstein                            | SD | Sudan  |    |                          |
| DK | Denmark                  | LK | Sri Lanka                                | SE | Sweden                                       |    |                          |
| EE | Estonia                  | LR | Liberia                                  | SG | Singapore                                    |    |                          |

- 1 -

Description

## Chimeric Adenoviral Vectors

5 Introduction

The present invention relates to chimeric adenoviral vectors, that is, vectors comprising DNA from more than one serotype of adenovirus, which offer enhanced infection efficiency of target cells in order to deliver one or more therapeutically useful nucleotide sequences, including transgenes, therein. Such a nucleotide  
10 sequence may comprise a gene not otherwise present in the target cell that codes for a therapeutic and/or biologically active protein, or may represent, for example, an active copy of a gene that is already present in the target cell, but in a defective or deficient form.

15 Background of the Invention

One of the fundamental challenges now facing medical practitioners is that although the defective genes that are associated with numerous inherited diseases (or that represent disease risk factors including for various cancers) have been isolated and characterized, methods to correct the disease states themselves by providing  
20 patients with normal copies of such genes (the technique of gene therapy) are substantially lacking. Accordingly, the development of improved methods of intracellular delivery therefor is of great medical importance. Examples of diseases that it is hoped can be treated by gene therapy include inherited disorders such as cystic fibrosis, Gaucher's disease, Fabry's disease, and muscular dystrophy.

25 Representative of acquired disorders that can be treated are: (1) for cancers: multiple myeloma, leukemias, melanomas, ovarian carcinoma and small cell lung cancer; (2) for cardiovascular conditions: progressive heart failure, restenosis, and hemophilias; and (3) for neurological conditions: traumatic brain injury.

- 2 -

Gene therapy requires successful transfer of nucleic acid to the target cells of a patient. Gene transfer may generally be defined as the process of introducing an expressible polynucleotide (for example a gene, a cDNA, or an mRNA patterned thereon) into a cell. In a particular application of this approach, successful expression  
5 of an encoding polynucleotide leads to production in the cells of a normal protein and leads to correction of a disease state associated with an abnormal gene. Therapies based on providing such proteins directly to target cells (protein replacement therapy) have generally proved ineffective since, for example, the cell membrane presents a selectively permeable barrier to entry. Thus there is great interest in alternative  
10 methods to cause delivery of therapeutic proteins, especially by transfer of the relevant polynucleotide, often referred to as a transgene.

Viral vectors have been used with increasing frequency to date to deliver transgenes to target cells. Most attempts to use viral vectors for gene therapy have relied on retrovirus-based vectors, chiefly because of their ability to integrate into the  
15 cellular genome. However, the disadvantages of retroviral vectors are becoming increasingly clear, including their tropism for dividing cells only, the possibility of insertional mutagenesis upon integration into the cell genome, decreased expression of the transgene over time, rapid inactivation by serum complement, and the possibility of generation of replication-competent retroviruses. See, for example, D. Jolly, et al.,  
20 Cancer Gene Therapy, 1, 1994, pp. 51-64, and C.P. Hodgson, et al., Bio Technology, 13, 1995, pp. 222-225. Such disadvantages have led to the development of other viral-based vector systems, including those derived from adenoviruses.

Adenovirus (Ad) is a nuclear DNA virus with a genome of about 36 kb, which has been well-characterized through studies in classical genetics and molecular  
25 biology. A detailed discussion of adenovirus is found in Thomas Shenk, "Adenoviridae and their Replication", and M. S. Horwitz, "Adenoviruses", Chapters 67 and 68, respectively, in Virology, B.N. Fields et al., eds., 2nd edition, Raven Press, Ltd., New York, 1996, and reference therein is found to numerous aspects of adenovirus pathology, epidemiology, structure, replication, genetics and classification.

- 3 -

In a simplified form, the adenoviral genome is classified into early (known as E1-E4) and late (known as L1-L5) transcriptional units, referring to the generation of two temporal classes of viral proteins. The demarcation between these events is viral DNA replication.

5       The human adenoviruses are divided into numerous serotypes (approximately 47, numbered accordingly and classified into 6 subgroups: A, B, C, D, E and F), based upon properties including hemagglutination of red blood cells, oncogenicity, DNA base and protein amino acid compositions and homologies, and antigenic relationships. Additional background information concerning Ad serotype  
10   classification, including that for subgroup D, can be found, for example, in F. Deryckere et al., *Journal of Virology*, 70, 1996, pp. 2832-2841; and A. Bailey et al., *Virology*, 205, 1994, pp. 438-452, and in other art-recognized references.

Adenoviruses are nonenveloped, regular icosahedrons (having 20 triangular surfaces and 12 vertices) that are about 65-80 nm in diameter. A protein called fiber  
15   projects from each of these vertices. The fiber protein is itself generally composed of 3 identical polypeptide chains, although the length thereof varies between serotypes. The protein coat (capsid) is composed of 252 subunits (capsomeres), of which 240 are hexons, and 12 are pentons. Each penton comprises a penton base, on the surface of the capsid, and a fiber protein projecting from the base. The Ad 2 penton base protein,  
20   for example, has been determined to be a 8 x 9 nm ring shaped complex composed of 5 identical protein subunits of 571 amino acids each.

Current understanding of adenovirus-cell interactions suggests that adenovirus utilizes two cellular receptors to attach to, and then infect a target cell. It has been further suggested that the fiber protein of an infecting adenovirus first attaches to a  
25   receptor, the identity of which is still unknown, and then penton base attaches to a further receptor, often a protein of the alpha integrin family. It has been determined that alpha-integrins often recognize short amino acid sequences on other cellular proteins for attachment purposes including the tripeptide sequence Arg-Gly-Asp (abbreviated RGD). An RGD sequence is also found in the penton base protein of

- 4 -

adenovirus and is currently understood in the art to mediate attachment of Ad to alpha integrins.

Recombinant adenoviruses have several advantages for use as gene transfer vectors, including tropism for both dividing and non-dividing cells, minimal  
5 pathogenic potential, ability to replicate to high titer for preparation of vector stocks, and the potential to carry large inserts (Berkner, K.L., Curr. Top. Micro. Immunol. 158:39-66, 1992; Jolly, D., Cancer Gene Therapy 1:51-64, 1994).

The carrying capacity of an adenovirus vector is proportional to the size of the adenovirus genome present in the vector. For example, a capacity of about 8 kb can  
10 be created from the deletion of certain regions of the virus genome dispensable for virus growth, e.g., E3, and the deletion of a genomic region such as E1 whose function may be restored in trans from 293 cells (Graham, F.L., J. Gen. Virol. 36:59-72, 1977) or A549 cells (Imler et al., Gene Therapy 3:75-84, 1996). Such E1-deleted vectors are rendered replication-defective, which is desirable for the engineering of adenoviruses  
15 for gene transfer. The upper limit of vector DNA capacity for optimal carrying capacity is about 105%-108% of the length of the wild-type genome. Further adenovirus genomic modifications are possible in vector design using cell lines which supply other viral gene products in trans, e.g., complementation of E2a (Zhou et al., J. Virol. 70:7030-7038, 1996), complementation of E4 (Krougliak et al., Hum. Gene  
20 Ther. 6:1575-1586, 1995; Wang et al., Gene Ther. 2:775-783, 1995), or complementation of protein IX (Caravokyri et al., J. Virol. 69:6627-6633, 1995; Krougliak et al., Hum. Gene Ther. 6:1575-1586, 1995). Maximal carrying capacity can be achieved using adenoviral vectors deleted for all viral coding sequences (Kochanek et al., Proc. Natl. Acad. Sci. USA 93:5731-5736, 1996; Fisher et al.,  
25 Virology 217:11-22, 1996).

Transgenes that have been expressed to date by adenoviral vectors include p53 (Wills et al., Human Gene Therapy 5:1079-188, 1994); dystrophin (Vincent et al., Nature Genetics 5:130-134, 1993; erythropoietin (Descamps et al., Human Gene Therapy 5:979-985, 1994; ornithine transcarbamylase (Stratford-Perricaudet et al.,

- 5 -

Human Gene Therapy 1:241-256, 1990; We et al., J. Biol. Chem. 271:3639-3646, 1996); adenosine deaminase (Mitani et al., Human Gene Therapy 5:941-948, 1994); interleukin-2 (Haddada et al., Human Gene Therapy 4:703-711, 1993); and  $\alpha$ 1-antitrypsin (Jaffe et al., Nature Genetics 1:372-378, 1992); thrombopoietin  
5 (Ohwada et al., Blood 88:778-784, 1996); and cytosine deaminase (Ohwada et al., Hum. Gene Ther. 7:1567-1576, 1996).

The particular tropism of adenoviruses for cells of the respiratory tract has particular relevance to the use of adenovirus in gene therapy for cystic fibrosis (CF), which is the most common autosomal recessive disease in Caucasians. The disease is  
10 caused by the presence of one or more mutations in the gene that encodes a protein known as cystic fibrosis transmembrane conductance regulator (CFTR), and which regulates the movement of ions (and therefore fluid) across the cell membrane of epithelial cells, including lung epithelial cells. Abnormal ion transport in airway cells leads to abnormal mucous secretion, inflammation and infection, tissue damage,  
15 and eventually death. Mutations in the CFTR gene that disturb the cAMP-regulated Cl<sup>-</sup> channel in airway epithelia result in pulmonary dysfunction (Zabner et al., Nature Genetics 6:75-83, 1994). Adenovirus vectors engineered to carry the CFTR gene have been developed (Rich et al., Human Gene Therapy 4:461-476, 1993) and studies have shown the ability of these vectors to deliver CFTR to nasal epithelia of CF patients  
20 (Zabner et al., Cell 75:207-216, 1993), the airway epithelia of cotton rats and primates (Zabner et al., Nature Genetics 6:75-83, 1994), and the respiratory epithelium of CF patients (Crystal et al., Nature Genetics 8:42-51, 1994). Recent studies have shown that administering an adenoviral vector containing a DNA sequence encoding CFTR to airway epithelial cells of CF patients can restore a functioning chloride ion channel  
25 in the treated epithelial cells (Zabner et al., J. Clin. Invest. 97:1504-1511, 1996; U.S. Patent No. 5,670,488 issued September 23, 1997).

Serotype classification is partly based on viral surface protein sequence variation. Because the infectious capabilities of the virus are associated with the surface protein interactions of the virus with cellular proteins, the serotype is an

- 6 -

important determinant of viral entry into target cells, and can account for the infectious heterogeneity of adenovirus serotypes. Most adenoviral vectors have been constructed using adenovirus serotypes from the well-studied group C adenoviruses, especially Ad 2 and Ad 5. However, other adenovirus serotypes display infectious  
5 properties that are relevant to the further design of improved adenoviral vectors, for example, those derived from subgroup D, which display enhanced tropism for human airway epithelial cells.

It is widely hoped that gene therapy will provide a long lasting and predictable form of therapy for certain disease states, and it is likely the only form of therapy  
10 suitable for many inherited diseases. Although adenoviral vectors are currently in clinical use and have shown therapeutic promise, a need remains to improve the infection efficiency of these vectors in order to further improve their gene transfer capabilities. The present invention addresses this goal.

#### 15 Summary Of The Invention

The present invention provides for chimeric adenoviral vectors which offer enhanced infection efficiency of target cells for the delivery of one or more transgenes. In a representative aspect of the invention, the vectors comprise nucleotide sequences coding for therapeutically useful proteins and have enhanced tropism for airway  
20 epithelial cells.

Accordingly, there are provided chimeric adenoviral vectors comprising nucleotide sequence of a first adenovirus, wherein at least one gene of said first adenovirus encoding a protein that facilitates binding of said vector to a target mammalian cell, or internalization thereof within said cell, is replaced by the  
25 corresponding gene from a second adenovirus belonging to subgroup D. These vectors may further comprising a transgene operably linked to a eucaryotic promoter or other regulatory elements to allow for expression therefrom in a mammalian cell. In a representative aspect thereof, the replaced encoding sequence codes for Ad fiber, hexon or penton base.



- 7 -

In a further preferred embodiment of the invention, there are provided chimeric adenoviral vectors comprising nucleotide sequence of a first adenovirus, wherein a portion of a gene thereof encoding a protein that facilitates binding of said vector to a target mammalian cell, or internalization thereof within said cell, is replaced by a  
5 portion of the corresponding gene from a second adenovirus belonging to subgroup D. These vectors may further comprising a transgene operably linked to a eucaryotic promoter or other regulatory elements to allow for expression therefrom in a mammalian cell. In a representative aspect thereof, the replaced encoding sequence codes for a portion of Ad fiber, hexon or penton base.

10 Preferably, the second adenovirus is a member of subgroup D, and the replaced nucleotide sequence encodes a polypeptide selected from the group consisting of Ad fiber, a fragment of Ad fiber, Ad hexon, a fragment of Ad hexon, Ad penton base, and a fragment of Ad penton base. In a preferred embodiment, said second adenovirus is selected from the group consisting of serotypes Ad 9, Ad 15, Ad  
15 17, Ad 19, Ad 20, Ad 22, Ad 26, Ad 27, Ad 28, Ad 30, and Ad 39. In preferred embodiments of the chimeric adenoviral vectors, the first adenovirus is selected from the group consisting of Ad 2, Ad 5, and Ad 12.

The invention is also directed to compositions comprising the chimeric adenoviral vectors of the invention. Additional aspects of the invention include  
20 methods to use the chimeric adenoviral vectors of the invention to deliver transgenes to mammalian target cells, for example, to the airway epithelial cells of patients.

A still further representative aspect of the invention involves a method of providing a therapeutic and/or biologically active protein to the airway epithelial cells of a patient by administering to said cells an adenoviral vector comprising elements of  
25 an Ad 17 genome, and a transgene encoding said therapeutic protein that is operably linked to a eucaryotic promoter to allow for expression therefrom in a mammalian cell, under conditions whereby the transgene encoding said therapeutic protein is expressed, and therapeutic benefit is produced in said airway epithelial cells.

- 8 -

These and other aspects of the present invention are described in the Detailed Description of the Invention which follows directly.

Brief Description of the Drawings

5       FIGURE 1 depicts infection of NHBE cells by Ad 2.

FIGURE 2 depicts infection of NHBE cells by Ad 17.

FIGURE 3 plots the result of binding to human nasal polyp epithelial cell isolates by Ad 2 and Ad 17.

FIGURE 4 is a map of the vector Ad2/ $\beta$ gal-2/fiber Ad 17.

10       FIGURE 5 shows a comparison of the amino acid sequence of penton base from Ad 17 (top) [SEQ ID NO: 4] and Ad 2 (bottom) [SEQ ID NO: 5], and further depicts the variable RGD containing region.

FIGURE 6 depicts an amino acid sequence pileup for penton base from particular Ad serotypes, including f10 (from fowl) [SEQ ID NO: 6 through SEQ ID  
15 NO: 10].

FIGURE 7 shows a comparison of the amino acid sequence of fiber from Ad 17 (top) [SEQ ID NO: 11] and Ad 2 (bottom) [SEQ ID NO: 12].

FIGURE 8 depicts an amino acid sequence pileup for fiber from particular Ad serotypes [SEQ ID NO: 11 through SEQ ID NO: 22], including two forms of serotype  
20 40 (40-1 and 40-2) which differ in that one variant has two (but non-identical) copies of the fiber gene.

FIGURE 9 shows the infection efficiency of colon cancer cell lines by adenovirus serotypes.

FIGURE 10 shows the infection efficiency of cancer cell lines by adenovirus  
25 serotypes.

Provided in the Sequence Listing attached hereto are also:

SEQ ID NO: 1, the complete nucleotide sequence of Ad 17;

SEQ ID NO: 2, the complete encoding nucleotide sequence for Ad 17 fiber;

- 9 -

SEQ ID NO: 3, the complete encoding nucleotide sequence for Ad 17 penton base.

#### Detailed Description of the Invention

5           The present invention provides for chimeric adenoviral vectors comprising nucleotide sequence of a first adenovirus, wherein at least one gene of said first adenovirus encoding a protein that facilitates binding of said vector to a target mammalian cell, or internalization thereof within said cell, is replaced by the corresponding gene from a second adenovirus belonging to subgroup D, said vectors  
10 further comprising a transgene operably linked to a eucaryotic promoter to allow for expression therefrom in a mammalian cell. In a representative aspect thereof, the replaced encoding sequence correspond to the gene encoding the Ad fiber, hexon or penton base proteins, or combinations thereof.

          In a further preferred embodiment of the invention, there are provided chimeric  
15 adenoviral vectors comprising nucleotide sequence of a first adenovirus, wherein a portion of a gene thereof encoding a protein that facilitates binding of said vector to a target mammalian cell, or internalization thereof within said cell, is replaced by a portion of the corresponding gene from a second adenovirus belonging to subgroup D, said vectors further comprising a transgene operably linked to a eucaryotic promoter to  
20 allow for expression therefrom in a mammalian cell. In a representative aspect thereof, the replaced encoding sequence codes for a portion of the Ad fiber, hexon or penton base proteins, or combinations thereof. Where a portion of a gene from a second adenovirus is used to construct a chimeric adenoviral vector, such sequence will have a length sufficient to confer a desired serotypic-specific virus-cell interaction to the  
25 vector.

          The present invention involves the recognition that adenoviral vectors that are either based substantially upon the genome of Ad serotypes classified in subgroup D, or that contain certain Ad-protein encoding polynucleotide sequences of subgroup D adenovirus, are particularly effective at binding to, and internalizing within, human

- 10 -

cells, such that therapeutic transgenes included in the adenoviral vector are efficiently expressed. This discovery is particularly surprising given that adenovirus serotypes of subgroup D are not clinically associated with human respiratory disease, and that, for example association with conjunctivitis is more typical. The recognition of this

5 tropism is of particular relevance for the treatment by gene therapy of recognized disease states such as cystic fibrosis or  $\alpha$  1-antitrypsin deficiency. This discovery is particularly surprising given that adenovirus serotypes of subgroup D are not clinically associated with human respiratory disease, and that, for example association with

10 conjunctivitis is more typical. The recognition of this tropism is of particular relevance for the treatment by gene therapy of recognized disease states such as cystic fibrosis or  $\alpha$  1-antitrypsin deficiency.

In a representative aspect of the invention, the adenoviral vectors further comprise nucleotide sequences coding for one or more transgenes and have enhanced tropism for airway epithelial cells. Preferably, the chimeric adenoviral vectors are

15 replication-defective, a feature which contributes to the enhanced safety of adenoviral vectors administered to individuals.

Preferably, the second adenovirus is a member of subgroup D, and the replaced nucleotide sequence encodes a polypeptide selected from the group consisting of Ad fiber, a fragment of Ad fiber, Ad hexon, a fragment of Ad hexon, Ad penton base, and

20 a fragment of Ad penton base. In a preferred embodiment, said second adenovirus is selected from the group consisting of serotypes Ad 9, Ad 15, Ad 17, Ad 19, Ad 20, Ad 22, Ad 26, Ad 27, Ad 28, Ad 30, and Ad 39. In a most preferred embodiment, the second adenovirus is Ad 17. In other preferred embodiments of the chimeric adenoviral vectors, the first adenovirus is selected from the group consisting of Ad 2,

25 Ad 5, and Ad 12.

There is substantial evidence that any reported transforming properties of the E4 region of certain subgroup D serotypes do not extend to Ad serotypes whose use is preferred according to the practice of the present invention (see, for example, R. Javier

- 11 -

et al., Science, 257, 1992, pp. 1267-1271). It is expected also that, for example, individual ORFs of subgroup D E4 region, such as ORF1, could be deleted.

Additional aspects of the invention include methods to provide biologically active and/or therapeutic proteins to mammalian cells, including, but not limited to, the airway epithelial cells of individuals, in order to provide phenotypic benefit. According to this aspect of the invention, chimeric adenoviral vectors are used in which a nucleotide sequence of a first adenovirus is replaced by the corresponding nucleotide sequence of a second adenovirus. Preferably, the second adenovirus is a member of subgroup D, and the replaced nucleotide sequence encodes a polypeptide encoding all or part of Ad fiber, Ad hexon, or Ad penton base, or combinations thereof.

A still further representative aspect of the invention involves providing a biologically active and/or therapeutic protein in the airway epithelial cells of a patient by administering to said cells an adenoviral vector comprising elements of an Ad 17 genome, and a transgene encoding said protein that is operably linked to a eucaryotic promoter to allow for expression therefrom in a mammalian cell, under conditions whereby the transgene encoding said protein is expressed, and the desired phenotypic benefit is produced in said airway epithelial cells. According to the practice of the invention, it is preferred that an chimeric adenovirus vector utilized to deliver a transgene to the respiratory epithelium (including that of the nasal airway, trachea, and bronchi and alveoli of the lung), or to other tissues of the body, comprise serotypes within subgroup D, as such classification is recognized in the art.

In order to construct the chimeric adenoviral vectors of the invention, reference may be made to the substantial body of literature on how such vectors may be designed, constructed and propagated using techniques from molecular biology and microbiology that are well-known to the skilled artisan. Specific examples of adenoviral vector genomes which can be used as the backbone for a chimeric adenoviral vector of the invention include, for example, Ad2/CFTR-1 and Ad2/CFTR-2 and others described in U. S. Patent No. 5,670,488, issued September 23, 1997

- 12 -

(incorporated herein by reference). Such vectors may include deletion of the E1 region, partial or complete deletion of the E4 region, and deletions within, for example, the E2 and E3 regions. Within the scope of the invention are, for example, chimeric vectors which contain an Ad 2 backbone with one or more Ad 17 capsid proteins or fragments thereof in the virus. Other adenoviral vector genomic designs which can be used in the chimeric adenoviral vectors of the invention include those derived from allowed U.S. Patent Application Serial No. 08/409,874, filed March 24, 1995, and allowed U.S. Patent Application Serial No. 08/540,077, filed October 6, 1995 (both incorporated herein by reference).

10 To construct the recombinant chimeric adenoviral vectors of the invention which contain a transcription unit, the skilled artisan can use the standard techniques of molecular biology to engineer a transgene or a capsid protein into a backbone vector genome (Berkner, K.L., Curr. Top. Micro. Immunol. 158:39-66, 1992). For example, a plasmid containing a transgene and any operably linked regulatory elements inserted into an adenovirus genomic fragment can be co-transfected with a linearized viral genome derived from an adenoviral vector of interest into a recipient cell under conditions whereby homologous recombination occurs between the genomic fragment and the virus. Preferably, a transgene is engineered into the site of an E1 deletion. As a result, the transgene is inserted into the adenoviral genome at the site in which it was cloned into the plasmid, creating a recombinant adenoviral vector. The chimeric adenoviral vectors can also be constructed using standard ligation techniques, for example, removing a restriction fragment containing a fiber gene from a first adenovirus and ligating into that site a restriction fragment containing a fiber gene from a second adenovirus. A representative example of a chimeric adenoviral vector of the invention is Ad2/ $\beta$ gal-2 fiber 17 (exemplified in Example 6).

25 Construction of the chimeric adenoviral vectors can be based on adenovirus DNA sequence information widely available in the field, e.g., nucleic acid sequence databases such as GenBank.

- 13 -

Preparation of replication-defective chimeric adenoviral vector stocks can be accomplished using cell lines that complement viral genes deleted from the vector, e.g., 293 or A549 cells containing the deleted adenovirus E1 genomic sequences. The use of HER3 cells (human embryonic retinoblasts transformed by Ad 12), as a  
5 complementing cell line is of note. After amplification of plaques in suitable complementing cell lines, the viruses can be recovered by freeze-thawing and subsequently purified using cesium chloride centrifugation. Alternatively, virus purification can be performed using chromatographic techniques, e.g., as set forth in International Application No. PCT/US96/13872, filed August 30, 1996, incorporated  
10 herein by reference.

Titers of replication-defective chimeric adenoviral vector stocks can be determined by plaque formation in a complementing cell line, e.g., 293 cells. End-point dilution using an antibody to the adenoviral hexon protein may be used to quantitate virus production or infection efficiency of target cells (Armentano et al.,  
15 Hum. Gene Ther. 6:1343-1353, 1995, incorporated herein by reference).

Transgenes which can be delivered and expressed from a chimeric adenoviral vector of the invention include, but are not limited to, those encoding enzymes, blood derivatives, hormones, lymphokines such as the interleukins and interferons, coagulants, growth factors, neurotransmitters, tumor suppressors, apolipoproteins,  
20 antigens, and antibodies, and other biologically active proteins. Specific transgenes which may be encoded by the chimeric adenoviral vectors of the invention include, but are not limited to, cystic fibrosis transmembrane regulator (CFTR), dystrophin, glucocerebrosidase, tumor necrosis factor, p53, p21, herpes simplex thymidine kinase and gancyclovir, retinoblastoma (Rb), and adenosine deaminase (ADA). Transgenes  
25 encoding antisense molecules or ribozymes are also within the scope of the invention. The vectors may contain one or more transgenes under the control of one or more regulatory elements.

In addition to containing the DNA sequences encoding one or more transgenes, the chimeric adenoviral vectors of the invention may contain any

- 14 -

expression control sequences such as a promoter or enhancer, a polyadenylation element, and any other regulatory elements that may be used to modulate or increase expression, all of which are operably linked in order to allow expression of the transgene. The use of any expression control sequences, or regulatory elements,  
5 which facilitate expression of the transgene is within the scope of the invention. Such sequences or elements may be capable of generating tissue-specific expression or be susceptible to induction by exogenous agents or stimuli.

Infection of target cell by the chimeric adenoviral vectors of the invention may also be facilitated by the use of cationic molecules, such as cationic lipids as disclosed  
10 in PCT Publication No. WO96/18372, published June 20, 1996, incorporated herein by reference.

Cationic amphiphiles have a chemical structure which encompasses both polar and non-polar domains so that the molecule can simultaneously facilitate entry across a lipid membrane with its non-polar domain while its cationic polar domain attaches  
15 to a biologically useful molecule to be transported across the membrane.

Cationic amphiphiles which may be used to form complexes with the chimeric adenoviral vectors of the invention include, but are not limited to, cationic lipids, such as DOTMA (Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417, 1987) (N-[1-(2,3-dioletoxy)propyl]-N,N,N - trimethylammonium chloride); DOGS  
20 (dioctadecylamidoglycylspermine) (Behr et al., Proc. Natl. Acad. Sci. USA 86:6982-6986, 1989); DMRIE (1,2-dimyristyloxypropyl-3-dimethyl-hydroxyethyl ammonium bromide) (Felgner et al., J. Biol. Chem. 269:2550-2561, 1994; and DC-chol (3B [N-N', N'-dimethylaminoethane) -carbamoyl] cholesterol) (U.S. Patent No. 5, 283,185 to Epand et al.). The use of other cationic amphiphiles recognized in the art or which  
25 come to be discovered is within the scope of the invention.

In preferred embodiments of the invention, the cationic amphiphiles useful to complex with and facilitate transfer of the vectors of the invention are those lipids which are described in PCT Publication No. WO96/18372, published June 20, 1996, which is incorporated herein by reference. Preferred cationic amphiphiles described



- 15 -

herein to be used in the delivery of the plasmids and/or viruses are GL-53, GL-67, GL-75, GL-87, GL-89, and GL-120, including protonated, partially protonated, and deprotonated forms thereof. Further embodiments include the use of non-T-shaped amphiphiles as described on pp. 22-23 of the aforementioned PCT application,  
5 including protonated, partially protonated and deprotonated forms thereof. Most preferably, the cationic amphiphile which can be used to deliver the vectors of the invention is spermine cholesterol carbamate (GL-67).

In the formulation of compositions comprising the chimeric adenoviral vectors of the invention, one or more cationic amphiphiles may be formulated with neutral co-  
10 lipids such as dileoylphosphatidylethanolamine (DOPE) to facilitate delivery of the vectors into a cell. Other co-lipids which may be used in these complexes include, but are not limited to, diphtanoylphosphatidylethanolamine, lyso-phosphatidylethanolamines, other phosphatidylethanolamines, phosphatidylcholines, lyso-phosphatidylcholines and cholesterol. A preferred molar ratio of cationic  
15 amphiphile to colipid is 1:1. However, it is within the scope of the invention to vary this ratio, including also over a considerable range. In a preferred embodiment of the invention, the cationic amphiphile GL-67 and the neutral co-lipid DOPE are combined in a 1:2 molar ratio, respectively, before complexing with a chimeric adenoviral vector for delivery to a cell.

20 In the formulation of complexes containing a cationic amphiphile with a chimeric adenoviral vector, a preferred range of  $10^7$  -  $10^{10}$  infectious units of virus may be combined with a range of  $10^4$  -  $10^6$  cationic amphiphile molecules/viral particle.

The infection efficiency of the chimeric adenoviral vectors of the invention  
25 may be assayed by standard techniques to determine the infection of target cells. Such methods include, but are not limited to, plaque formation, end-point dilution using, for example, an antibody to the adenoviral hexon protein, and cell binding assays using radiolabelled virus. Improved infection efficiency may be characterized as an increase in infection of at least an order of magnitude with reference to a control virus. Where

- 16 -

a chimeric adenoviral vector encodes a marker or other transgene, relevant molecular assays to determine expression include the measurement of transgene mRNA, by, for example, Northern blot, S1 analysis or reverse transcription-polymerase chain reaction (RT-PCR). The presence of a protein encoded by a transgene may be detected by  
5 Western blot, immunoprecipitation, immunocytochemistry, or other techniques known to those skilled in the art. Marker-specific assays can also be used, such as X-gal staining of cells infected with a chimeric adenoviral vector encoding  $\beta$ -galactosidase.

In order to determine transgene expression and infection efficiency in vivo using the constructs and compositions of the invention, animal models may be  
10 particularly relevant in order to assess transgene persistence against a background of potential host immune response. Such a model may be chosen with reference to such parameters as ease of delivery, identity of transgene, relevant molecular assays, and assessment of clinical status. Where the transgene encodes a protein whose lack is associated with a particular disease state, an animal model which is representative of  
15 the disease state may optimally be used in order to assess a specific phenotypic result and clinical improvement. However, it is also possible that particular chimeric adenoviral vectors of the invention display enhanced infection efficiency only in human model systems, e.g., using primary cell cultures, tissue explants, or permanent cell lines. In such circumstances where there is no animal model system available in  
20 which to model the infection efficiency of a chimeric adenoviral vector with respect to human cells, reference to art-recognized human cell culture models will be most relevant and definitive.

Relevant animals in which the chimeric adenoviral vectors may be assayed include, but are not limited to, mice, rats, monkeys, and rabbits. Suitable mouse  
25 strains in which the vectors may be tested include, but are not limited to, C3H, C57Bl/6 (wild-type and nude) and Balb/c (available from Taconic Farms, Germantown, New York).

Where it is desirable to assess the host immune response to vector administration, testing in immune-competent and immune-deficient animals may be

- 17 -

compared in order to define specific adverse responses generated by the immune system. The use of immune-deficient animals, e.g., nude mice, may be used to characterize vector performance and persistence of transgene expression, independent of an acquired host response.

5           In a particular embodiment where the transgene is the gene encoding cystic fibrosis transmembrane regulator protein (CFTR) which is administered to the respiratory epithelium of test animals, expression of CFTR may be assayed in the lungs of relevant animal models, for example, C57Bl/6 or Balb/c mice, cotton rats, or Rhesus monkeys. Molecular markers which may be used to determine expression  
10   include the measurement of CFTR mRNA, by, for example, Northern blot, S1 analysis or RT-PCR. The presence of the CFTR protein may be detected by Western blot, immunoprecipitation, immunocytochemistry, or other techniques known to those skilled in the art. Such assays may also be used in tissue culture where cells deficient in a functional CFTR protein and into which the chimeric adenoviral vectors have  
15   been introduced may be assessed to determine the presence of functional chloride ion channels - indicative of the presence of a functional CFTR molecule.

          The chimeric adenoviral vectors of the invention have a number of in vivo and in vitro utilities. The vectors can be used to transfer a normal copy of a transgene encoding a biologically active protein to target cells in order to remedy a deficient or  
20   dysfunctional protein. The vectors can be used to transfer marked transgenes (e.g., containing nucleotide alterations) which allow for distinguishing expression levels of a transduced gene from the levels of an endogenous gene. The chimeric adenoviral vectors can also be used to define the mechanism of specific viral protein-cellular protein interactions that are mediated by specific virus surface protein sequences. The  
25   vectors can also be used to optimize infection efficiency of specific target cells by adenoviral vectors, for example, using a chimeric adenoviral vector containing Ad 17 fiber protein to infect human nasal polyp cells. Where it is desirable to use an adenoviral vector for gene transfer to cancer cells in an individual, a chimeric adenoviral vector can be chosen which selectively infects the specific type of target

- 18 -

cancer cell and avoids promiscuous infection. Where primary cells are isolated from a tumor in an individual requiring gene transfer, the cells may be tested against a panel of chimeric adenoviral vectors to select a vector with optimal infection efficiency for gene delivery. The vectors can further be used to transfer tumor antigens to dendritic  
5 cells which can then be delivered to an individual to elicit an anti-tumor immune response. Chimeric adenoviral vectors can also be used to evade undesirable immune responses to particular adenovirus serotypes which compromise the gene transfer capability of adenoviral vectors.

The present invention is further directed to compositions containing the  
10 chimeric adenoviral vectors of the invention which can be administered in an amount effective to deliver one or more desired transgenes to the cells of an individual in need of such molecules and cause expression of a transgene encoding a biologically active protein to achieve a specific phenotypic result. The cationic amphiphile-plasmid complexes or cationic amphiphile-virus complexes may be formulated into  
15 compositions for administration to an individual in need of the delivery of the transgenes.

The compositions can include physiologically acceptable carriers, including any relevant solvents. As used herein, "physiologically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents,  
20 isotonic and absorption delaying agents, and the like. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the compositions is contemplated.

Routes of administration for the compositions containing the chimeric adenoviral vectors of the invention include conventional and physiologically  
25 acceptable routes such as direct delivery to a target organ or tissue, intranasal, intravenous, intramuscular, subcutaneous, intradermal, oral and other parenteral routes of administration.

The invention is further directed to methods for using the compositions of the invention in vivo or ex vivo applications in which it is desirable to deliver one or more

- 19 -

transgenes into cells such that the transgene produces a biologically active protein for a normal biological or phenotypic effect. In vivo applications involve the direct administration of one or more chimeric adenoviral vectors formulated into a composition to the cells of an individual. Ex vivo applications involve the transfer of a composition containing the chimeric adenoviral vectors directly to autologous cells which are maintained in vitro, followed by readministration of the transduced cells to a recipient.

Dosage of the chimeric adenoviral vector to be administered to an individual for expression of a transgene encoding a biologically active protein and to achieve a specific phenotypic result is determined with reference to various parameters, including the condition to be treated, the age, weight and clinical status of the individual, and the particular molecular defect requiring the provision of a biologically active protein. The dosage is preferably chosen so that administration causes a specific phenotypic result, as measured by molecular assays or clinical markers. For example, determination of the infection efficiency of a chimeric adenoviral vector containing the CFTR transgene which is administered to an individual can be performed by molecular assays including the measurement of CFTR mRNA, by, for example, Northern blot, S1 or RT-PCR analysis or the measurement of the CFTR protein as detected by Western blot, immunoprecipitation, immunocytochemistry, or other techniques known to those skilled in the art. Relevant clinical studies which could be used to assess phenotypic results from delivery of the CFTR transgene include PFT assessment of lung function and radiological evaluation of the lung. Demonstration of the delivery of a transgene encoding CFTR can also be demonstrated by detecting the presence of a functional chloride channel in cells of an individual with cystic fibrosis to whom the vector containing the transgene has been administered (Zabner et al., J. Clin. Invest. 97:1504-1511, 1996). Transgene expression in other disease states can be assayed analogously, using the specific clinical parameters most relevant to the condition.

- 20 -

Dosages of a chimeric adenoviral vector which are effective to provide expression of a transgene encoding a biologically active protein and achieve a specific phenotypic result range from approximately  $10^8$  infectious units (I.U.) to  $10^{11}$  I.U. for humans.

5           It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subjects to be treated, each unit containing a predetermined quantity of active ingredient calculated to produce the specific phenotypic effect in association with the required  
10   physiologically acceptable carrier. The specification for the novel dosage unit forms of the invention are dictated by and directly depend on the unique characteristics of the chimeric adenoviral vector and the limitations inherent in the art of compounding. The principal active ingredient (the chimeric adenoviral vector) is compounded for convenient and effective administration in effective amounts with the physiologically  
15   acceptable carrier in dosage unit form as discussed above.

Maximum benefit and achievement of a specific phenotypic result from administration of the chimeric adenoviral vectors of the invention may require repeated administration. Such repeated administration may involve the use of the same chimeric adenoviral vector, or, alternatively, may involve the use of different  
20   chimeric adenoviral vectors which are rotated in order to alter viral antigen expression and decrease host immune response.

The practice of the invention employs, unless otherwise indicated, conventional techniques of protein chemistry, molecular virology, microbiology, recombinant DNA technology, and pharmacology, which are within the skill of the  
25   art. Such techniques are explained fully in the literature. See, e.g., Current Protocols in Molecular Biology, Ausubel et al., eds., John Wiley & Sons, Inc., New York, 1995, and Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Co., Easton, PA, 1985.

- 21 -

The invention is further illustrated by the following specific examples which are not intended in any way to limit the scope of the invention.

### Examples

5

#### Example 1 Infection of NHBE cells by adenovirus serotypes of subgroup D

Normal human bronchial epithelial ("NHBE") cells were obtained from Clonetics (San Diego, CA), and plated on Costar (Cambridge, MA) Transwell-Clear polyester membranes that were pre-coated with human placental collagen. The wells  
10 were placed in a cluster plate and cells were fed every day for one week by changing the medium in both the well and the plate. After one week the media was removed from the wells to create an air-liquid interface, and the cells were then fed only by changing the medium in the cluster plate, every other day for one week. Cells were infected at an moi of 1 by adding virus (see below) to the transwell, followed by an  
15 incubation time of 1.5-2 hours. At the end of the incubation period, the medium was removed and the cells were gently rinsed with fresh medium. Thirty-six hours post-infection the cells were fixed with 1:1 acetone:methanol, permeablized with a solution of 0.05% Tween 20 in PBS, and stained with FITC labeled anti-hexon antibody (Chemicon, Temecula, CA) to visualize cells that had been productively infected (i.e.  
20 to visualize virus replication). Cells were also subjected to the DAPI staining procedure in order to visualize the total number of nuclei. The results could be readily determined upon simple inspection.

Wild type Ad serotypes within subgroup D that were tested included 9, 15, 17, 19, 20, 22, 26, 27, 28, 30, and 39 (all from the American Type Culture Collection,  
25 Rockville, MD). An Ad 2 (obtained as DNA from BRL, Gaithersburg, MD, and used to transfect 293 cells in order to generate virus stock) was used as a control. Infection observed with all of the subgroup D serotypes was superior to that observed with Ad 2, with the best results being achieved with Ad 9, Ad 17, Ad 20, Ad 22, and Ad 30.

- 22 -

Additionally, it was determined that each of the above-mentioned serotypes of subgroup D was more effective in the NHBE cell assay under similar circumstances than any other serotype tested than belongs to a subgroup other than D. In this regard, the following serotypes were also tested: 31(subgroup A); 3(subgroup B); 7(subgroup B); 7a(subgroup B); 14(subgroup B); 4(subgroup E); and 41(subgroup F). In a further experiment, serotype 35 (subgroup A) may have performed as well as the least effective members of subgroup D that were tested.

#### Example 2 Infection of clinical isolate bronchial epithelial cells

10 Following generally the procedures of Example 1, human bronchial epithelial cells recovered from healthy human volunteers were infected with either Ad 2 (as above, Ad 2 DNA was obtained from BRL, and this DNA was used to transfect 293 cells to generate virus) (Figure 1), or Ad 17 (from ATCC) (Figure 2), all at an moi of 50. Cells were left in contact with virus for 30 minutes, 3 hours, or 12 hours.

15 The increased tropism of Ad 17 for human bronchial epithelial cells, compared with Ad 2, is readily apparent upon inspection of Figures 1 and 2. In the Figures, the right hand columns (panels D, E, and F, stained in blue) show total numbers of cells present (from DAPI staining as above), whereas the left hand columns (panels A, B, and C, stained in green) quantify adenovirus hexon protein present in the infected cells  
20 (from FITC-labeled anti-hexon antibody, as above). Panels A and D result from 30 minute incubation times, panels B and E result from 3 hour incubation times, and panels C and F result from 12 hour incubation times. As measured by the technique employed, infection of airway epithelia by Ad 17 is at least 50 fold greater than by Ad 2 for the thirty minute incubation time.

25

#### Example 3 Binding of Ad 2 and Ad 17 to human nasal polyp cell isolates

293 cells, a complementing cell line developed by Graham et al. (see Gen. Virol. , 36, 1977, pp. 59-72), were infected with either wild type Ad 2 or wild type Ad 17. Five hours post-infection the media was removed and replaced with methionine



- 23 -

free media containing  $S^{35}$  metabolic label (Amersham). After an additional six hours, fresh media was added and the labeling was allowed to proceed for a total of 18 hours, after which the  $S^{35}$  media was removed and replaced with fresh media. Thirty hours post-infection the cells were harvested and lysed and the labeled Ad 2 or Ad 17  
5 viruses were purified by CsCl gradient centrifugation. The recovered viruses were then used in an assay to determine their relative binding efficiency on human nasal polyp cells.

In order to perform the assay, ciliated human airway epithelial cells were recovered from nasal polyps of healthy volunteers. The results from two such isolates,  
10 NP-14 and NP-15, are reported here (see Figure 3). Radiolabeled virus was then incubated with the isolated cells in wells for specified times ( 5 or 30 minutes, see Figure 3). The cells were then rinsed and measured for radioactivity. Binding as reported in Figure 3 indicates the percent of input radioactivity that is cell associated. It was determined that for both cell isolate populations, using either 5 or 30 minute  
15 incubations, cell associated radioactivity was 10-fold enhanced if Ad 17 rather than Ad 2 was used.

#### Example 4 Fiber competition

20 A549 cells (a human lung carcinoma line, obtained from the American Type Culture Collection as ATCC CCL-185) were plated at  $3 \times 10^4$  cells per well in 96-well dishes. Since the number of receptor sites for adenovirus fiber on the cell surface has been estimated to be approximately  $10^5$  receptors per cell, the receptors in the plated cells were saturated, in this example, with  $0.1 \mu\text{g}$  of purified full length Ad 2 fiber  
25 protein (obtained from Paul Freimuth, Brookhaven National Laboratory, Upton, NY), which corresponds to approximately 100 molecules of fiber per receptor. Cells were incubated with Ad 2 fiber in PBS for two hours at  $37^\circ\text{C}$ .

- 24 -

The cells were subsequently infected at an moi of 1 (using either Ad 2 provided as above, or wild type Ad 17) for one hour, after which the cells were rinsed, and fresh medium was added. Control cultures were incubated with PBS with no added protein for two hours and then subsequently infected as described above. Forty  
5 hours post-infection the cells were fixed with 1:1 acetone:methanol, permeabilized with 0.05% Tween 20 in PBS and stained with FITC labeled anti- Ad 2 hexon antibody, as described in Example 1. As determined by this assay, the number of cells infected (stained) with Ad 2 was reduced by approximately 90% in cultures that were pre-incubated with Ad 2 fiber as compared to control cultures. However, no effect on  
10 Ad 17 infection was observed by the pre-incubation of A549 cells with full length Ad 2 fiber.

Example 5 Use of Ad 2 fiber knob in a binding competition  
experiment with Ad 2

15

Further competition experiments were performed with Ad 2 and Ad 17 fiber knobs that had been expressed and purified from E. coli. DNA sequences encoding both protein fragments were designed so that the fiber knobs expressed therefrom would contain histidine tags in order to permit nickel- column purification. The yield  
20 of soluble fiber knob trimer, purified by the Ni-NTA method (Qiagen, Chatsworth, CA), was ~25µg/50ml culture. A significant portion of the total knob protein expressed appeared to remain in a monomeric (and insoluble) form. The soluble trimeric material obtained was used for a preliminary competition experiment. Wild type Ad 2 and Ad 17 were used to infect A549 cells, or cells that had been pre-  
25 incubated with excess (about 100 molecules of trimer per receptor) Ad 2 fiber knob or Ad 17 fiber knob. The results indicated that Ad 2 fiber knob, but not Ad 17 knob, could block Ad 2 infection. Additionally, Ad 17 infection was not blocked by E. coli-expressed fiber knobs of either serotype, suggesting that the mechanism of Ad 2 and Ad 17 infections is different.

-25 -

#### Example 6 Construction of the chimeric vector Ad2/ $\beta$ gal-2/fiber Ad 17

The vector Ad2/ $\beta$ gal-2 was constructed as follows. A CMV $\beta$ gal expression  
5 cassette was constructed in a pBR322-based plasmid that contained Ad 2 nucleotides  
1-10,680 from which nucleotides 357-3328 were deleted. The deleted sequences were  
replaced with (reading from 5' to 3'): a cytomegalovirus immediate early promoter  
(obtained from pRC/CMV, Invitrogen), lacZ gene encoding  $\beta$ -galactosidase with a  
nuclear localization signal, and an SV40 polyadenylation signal (nucleotides 2533-  
10 2729). The resulting plasmid was used to generate Ad2/ $\beta$ gal-2 by recombination with  
Ad2E4ORF6 (D. Armentano et al., Human Gene Therapy , 6, 1995, pp 1343 -1353).

A chimeric Ad2/ $\beta$ gal-2/fiber Ad 17 viral vector (Figure 4) was then constructed  
as follows. pAdORF6 (D. Armentano et al., Human Gene Therapy , 6, 1995, pp 1343  
-1353) was cut with Nde and BamHI to remove Ad 2 fiber coding and polyadenylation  
15 signal sequences (nucleotides 20624-32815). An NdeI-BamHI fragment containing  
Ad 17 fiber coding sequence (nucleotides 30984-32095) was generated by PCR and  
ligated along with an SV40 polyadenylation signal into NdeI-BamHI cut pAdORF6 to  
generate pAdORF6fiber17. This plasmid was cut with PacI and then ligated to PacI-  
cut Ad2/ $\beta$ gal-2 DNA to generate Ad2/ $\beta$ gal-2fiber 17. Any desired transgene may be  
20 substituted in this construct for the reporter gene.

A similar construct can be prepared using a DNA sequence that encodes Ad 17  
penton base instead of Ad 17 fiber. Alternatively, only a subregion of the penton base  
of Ad 2 need be subject to replacement, such as by inserting into the vector a  
nucleotide encoding sequence corresponding to any amino acid subsequence of Ad 17  
25 penton base amino acids 283-348 ( see the marked sequence in Figure 5A) in  
replacement for any subsequence of Ad 2 penton base amino acids 290-403.  
Preferrably, the replaced sequence of Ad 2 and the inserted sequence of Ad 17  
includes the RGD domain of each. Use of nucleotide sequence corresponding to  
penton base amino acid sequence for other subgroup D serotypes is also within the

- 26 -

practice of the invention. It is also within the scope of the invention to replace a subregion of the fiber protein in the Ad 2 vector with a subregion from another adenovirus serotype, for example, Ad 17.

5    Example 7    Ad2/ $\beta$ gal-2f17 shows increased infection efficiency on human airway explants

Both human and monkey trachea explants, about 1 cm<sup>2</sup>, were placed on top of an agar support. Each explant was infected at an moi of 200 of either Ad2/ $\beta$ gal-2 or Ad2/ $\beta$ gal-2f17 assuming a cell density of  $1 \times 10^6$  per cm<sup>2</sup> of explant. Explants were  
10    exposed to virus for three hours and were then rinsed with NHBE media. Two days post-infection explants were stained with X-gal and infection efficiency was assessed. On the monkey explants Ad2/ $\beta$ gal-2 gave rise to a higher infection efficiency than Ad2/ $\beta$ gal-2f17. Patches of stained cells were detected in explants exposed to Ad2/ $\beta$ gal-2 but very few cells stained in explants exposed to Ad2/ $\beta$ gal-2f17. A  
15    different result was obtained on human trachea explants. On these explants Ad2/ $\beta$ gal-2f17 infection gave rise to a much higher infection efficiency than Ad2/ $\beta$ gal-2 infection. Approximately 5-10% of the cells in explants exposed to Ad2/ $\beta$ gal-2f17 stained with X-gal whereas very few cells were stained in explants exposed to Ad2/ $\beta$ gal-2. No background staining was observed in either monkey or human  
20    explants that were not exposed to virus.

The results indicate that the exchange of Ad 2 fiber for Ad 17 fiber in Ad2/ $\beta$ gal-2f17 was sufficient to significantly increase infection efficiency of human tracheal airway cells by an adenovirus type 2 based vector.

25    Example 8    Adenovirus subgroup screening on human cancer cell lines

Identification of adenovirus subgroup that best infects a particular tumor type may be useful in designing vectors to optimally target cancer cells in vivo. In order to determine the adenovirus subgroup that best infects a particular type of cancer cell, cancer cells were seeded into a 96 well plate and infected with an moi of 5. Infection

- 27 -

efficiency was determined by staining of infected cells using an anti-hexon antibody. The adenovirus subgroups were represented by the following serotypes: A: Ad 31; B: Ad 3; C: Ad 2; D: Ad 17; E: Ad 4; and F: Ad 41.

Subgroup D (Ad 17) has a significantly higher infection rate of the colon  
5 cancer cell line CaCo-2 than other cell types, with an infection rate of 70%, while Ad 2 only infected 20% of the cells (Figure 9).

Subgroup D (Ad 17) was effective in infecting ovarian cancer cell line SK-OV3. Infection was measured at 90% (Figure 10).

#### 10 Sequence Listing

Included herewith on the following pages are informal copies of SEQ ID NO: 1 through SEQ ID NO: 3.

1 CATCATCAAT AATATACCCC ACAAAGTAAA CAAAAGTTAA TATGCAAATG AGGTTTTTAAA  
61 TTTAGGGCGG GGCTACTGCT GATTGGCCGA GAAACGTTGA TGCAAATGAC GTCACGACGC  
121 ACGGCTAACG GTCGCCGCGG AGGCGTGGCC TAGCCCGGAA GCAAGTCGCG GGGCTGATGA  
181 CGTATAAAAA AGCGGACTTT AAACCCGGAA ACGGCCGATT TTCCCGCGGC CACGCCCGGA  
241 TATGAGGTAA TTCTGGGCGG ATGCAAGTGA AATTAGGTCA TTTTGGCGCG AAAACTGAAT  
301 GAGGAAGTGA AAAGTGAAAA ATACCGGTCC CGCCCAGGGC GGAATATTTA CCGAGGGCCG  
361 AGAGACTTTG ACCGATTACG TGTGGGTTC GATTGCGGTG TTTTTCGCG AATTTCCGCG  
421 TCCGTGTCAA AGTCCGGTGT TTATGTCACA GATCAGCTGA TCCACAGGTG ATTTAAACCA  
481 GTCGAGCCCG TCAAGAGGCC ACTCTTGAGT GCCAGCGAGT AGAGATTTCT CTGAGCTCCG  
541 CTCCAGAGT GTGAGAAAAA TGAGACACCT GCGCCTCCTG CCTGGAAGTGTG TGCCCTTGGA  
601 CATGGCCGCA TTATTGCTGG ATGACTTTGT GAGTACAGTA TTGGAGGATG AACTGCAACC  
661 AACTCCGTTT GAGCTGGGAC CCACACTTCA GGACCTCTAT GATTTGGAGG TAGATGCCCA  
721 GGAGGACGAC CCGAACGAAG ATGCTGTGAA TTTAATATTT CCAGAATCTC TGATTCTTCA  
781 GGCTGACATA GCCAGCGAAG CTCTACCTAC TCCACTTCAT ACTCCAACCTC TGTACCCAT  
841 ACCTGAATTG GAAGAGGAGG ACGAGTTAGA CCTCCGGTGT TATGAGGAAG GTTTTCCTCC  
901 CAGCGATTCA GAGGACGAAC AGGGTGAGCA GAGCATGGCT CTAATCTCAG ACTATGCTTG  
961 TGTGGTTGTG GAAGAGCATT TTGTGTTGGA CAATCCTGAG GTGCCCGGGC AAGGCTGTAA  
1021 ATCCTGCCAG TACCACCGGG ATAAGACCGG AGACACGAAC GCCTCCTGTG CTCTGTGTTA  
1081 CATGAAAAAG AACTTCAGCT TTATTTACAG TAAGTGGAGT GAATGTGAGA GAGGCTGAGT  
1141 GCTTAAGACA TAACTGGGTG ATGCTTCAAC AGCTGTGCTA AGTGTGGTTT ATTTTGTTC  
1201 TAGGTCCGGT GTCAGAGGAT GGTCATCACC CTCAGAAGAA GACCACCCGT GTCCCCCTGA  
1261 TCTGTCAGGC GAAACGCCCC TGCAAGTGCA CAGACCCACC CCAGTCAGAC CCAGTGGCGA  
1321 GAGGCGAGCA GCTGTTGAAA AAATTGAGGA CTTGTTACAT GACATGGGTG GGGATGAACC  
1381 TTTGGACCTG AGCTTGAAAC GTCCCAGGAA ACTAGGCGCA GCTGCGCTTA GTCATGTGTA  
1441 AATAAAGTTG TACAATAAAA ATTATATGTG ACGCATGCAA GGTGTGGTTT ATGACTCATG  
1501 GGCGGGGCTT AGTTCTATAT AAGTGGCAAC ACCTGGGCAC TGGAGCACAG ACCTTCAGGG  
1561 AGTTCTGAT GGATGTGTGG ACTATCCTTG CAGACTTTAG CAAGACACGC CGGCTTGATG  
1621 AGGATAGTTC AGACGGGTGC TCCGGTCTCT GGAGACACTG GTTTGGAACCT CCTCTATCTC  
1681 GCCTGGTGTA CACAGTTAAA AAGGATTATA ACGAGGAATT TGAAAATCTT TTTGCTGATT  
1741 GCTCTGGCCT GCTAGATTCT CTGAATCTCG GCCACCAGTC CCTTTTCCAG GAAAGGGTAC  
1801 TCCACAGCCT TGATTTTTC AGCCACGGG CCACTACAGC CGGGGTGCTT TTTGTGGTTT  
1861 TTTGTTGTA CAAATGGAGC CAGAACACCC AACTGAGCAG GGGCTACATT CTGGACTTCG  
1921 CAGCCATGCA CCTGTGGAGG GCATGGGTCA GGCAGCGGGG ACAGAGAATC TTGAACTACT  
1981 GGCTTCTACA GCCAGCAGCT CCGGGTCTTC TTCGTCTACA CAGACAAACA TCCATGTTGG  
2041 AGGAAGAAAT GAGGCAGGCC ATGGACGAGA ACCCGAGGAG CGGTCTGGAC CCTCCGTCGG  
2101 AAGAGGAGTT GGATTGAATC AGGTATCCAG CCTGTACCCA GAGCTTAGCA AGGTGCTGAC  
2161 ATCCATGGCC AGGGGAGTGA AGAGGGAGAG GAGCGATGGG GGCAATACCG GGATGATGAC  
2221 CGAGCTGACG GCCAGTCTGA TGAATCGCAA GCGCCAGAG CGCCTTACCT GTAGCAGCT  
2281 ACAGCAGGAG TGCAGGGATG AGTTGGGCTT GATGCAGGAT AAATATGGCC TGGAGCAGAT  
2341 AAAAACCCTT TGGTTGAACC CAGATGAGGA TTGGGAGGAG GCTATTAAGA AGTATGCCAA  
2401 GATAGCCCTG CGCCAGATT GCAAAGTACAT AGTGACCAAG ACCGTGAATA TCAGACATGC  
2461 TGCTACATCT CGGGGAACGG GGCAGAGGTG GTCATTGATA CCTTGACAA GGCCGCCTTT  
2521 AGGTGTTGCA TGATGGGAAT GAGAGCCGGA GTGATGAATA TGAATTCCAT GATCTTTATG  
2581 AACATGAAGT TCAATGGAGA GAAGTTTAAT GGGGTGCTGT TCATGGCCAA CAGCCACATG  
2641 ACCCTGCATG GCTGCGACTT TTTCCGCTTT AACAATATGT GCGCAGAGGT CTGGGGCGCT  
2701 TCCAAGATCA GGGGATGTAA GTTTTATGGC TGCTGGATGG GCGTGGTCGG AAGACCCAAG  
2761 AGCGAGATGT CTGTGAAGCA GTGTGTGTTT GAGAAATGCT ACCTGGGAGT CTCTACCGAG  
2821 GGCAATGCTA GAGTGAGGCA CTGCTCTTCC CTGGAGACGG GCTGCTTCTG CCTGGTGAAG  
2881 GGCACAGCCT CTCTGAAGCA TAATATGGTG AAGGGCTGCA CGGATGAGCG CATGTACAAC  
2941 ATGCTGACTG CCACTCGGGG GTCTGTCTATA TCCTGAAGAA CATCCATGTG ACCTCCACC  
3001 CCAGAAAGAA GTGGCCAGTG TTTGAGAATA ACATGCTGAT CAAGTGCCAC ATGCACCTGG  
3061 GCGCCAGAAG GGGCACCTTC CAGCCGTACC AGTGCAACTT TAGCCAGACC AAGCTGCTGT  
3121 TGGAGAACGA TGCCCTTCTC AGGGTGAACC TGAACGGCAT CTTTGACATG GATGTCTCGG  
3181 TGTACAAGAT CCTGAGATAC GATGAGACCA AGTCCAGGGT GCGCGCTTGC GAGTGCGGGG  
3241 GCAGACACAC CAGGATGCAG CCAGTGCCCC TGGATGTGAC CGAGGAGCTG AGACCAGACC  
3301 ACCTGGTGAT GGCCTGTACC GGGACCGAGT TCAGCTCCAG TGGGGAGGAC ACAGATTAGA  
3361 GGTAGGTTTG AGTAGTGGGC GTGGCTAAGG TGACTATAAA GSCGGGTGTC TTACGAGGGT

3421 CTTTTTGCTT TTCTGCAGAC ATCATGAACG GGACCGGCGG GGCCTTCGAA GGGGGGCTTT  
3481 TTAGCCCTTA TTTGACAACC CGCCTGCCAG GATGGGCCGG AGTTCGTCAG AATGTGATGG  
3541 GATCGACGGT GGACGGGCGC CCAGTGCTTC CAGCAAATTC CTCGACCATG ACCTACGCGA  
3601 CCGTGGGGAA CTCGTGCTT GACAGCACCG CCGCAGCCGC GGCAGCCGCA GCCGCCATGA  
3661 CAGCGACGAG ACTGGCCTCG AGCTACATGC CCAGCAGCAG CAGTAGCCCC TCTGTGCCCA  
3721 GTTCCATCAT CGCCGAGGAG AACTGCTGGC CCTGCTGGCC GAGCTGGAAG CCCTGAGCCG  
3781 CCAGCTGGCC GCCCTGACCC AGCAGGTGTC CGAGCTCCGC GAACAGCAGC AGCAAAATAA  
3841 ATGATTCAAT AAACACATAT TCTGATTCAA ACAGCAAAGC ATCTTTATTA TTTATTTTTT  
3901 CGCGCGCGGT AGGCCCTGGT CCACCTCTCC CGATCATTGA GAGTGCGGTG GATTTTTTCC  
3961 AAGACCCGGT AGAGGTGGGA TTGGATGTTG AGGTACATGG GCATGAGCCC GTCCCGGGGG  
4021 TGGAGGTAGC ACCACTGCAT GGCCTCGTGC TCTGGGGTCG TGTGTAGAT GATCCAGTCA  
4081 TAGCAGGGGC GCTGGGCGTG GTGCTGGATG ATGTCCTTGA GGAGGAGACT GATGGCCACG  
4141 GGGAGCCCCT TGGTGTAGGT GTTGGCAAAG CGGTTGAGCT GGGAGGGATG CATGCGGGGG  
4201 GAGATGATGT GCAGTTTGGC CTGGATCTTG AGGTTGGCGA TGTGGCCACC CAGATCCCCG  
4261 CGGGGGTTCA TGTGTGCAG GACCACCAGG ACGGTGTAGC CCGTGCACCT GGGGAACCTA  
4321 TCATGCAACT TGGAAGGGAA TGCCTGGAAG AATTTGGAGA CGCCCTTGTG CCCGCCAGG  
4381 TTTTCCATGC ACTCATCCAT GATGATGGCG ATGGGCCCGT GGGCTGCGGC TTTGGCAAAG  
4441 ACGTTTCTGG GGTGAGAGAC ATCATAATTA TGCTCCTGGG TGAGATCATC ATAAGACATT  
4501 TTAATGAATT TTGGGCGGAG GGTGCCAGAT TGGGGGACGA TGGTTTCCCT CGGGCCCCGG  
4561 GGCGAAGTTC CCCTCGCAGA TCTGCATCTC CCAGGCTTTC ATCTCGGAGG GGGGGATCAT  
4621 GTCCACCTGC GGGGCGATGA AAAAAACGGT TTCCGGGGCG GGGGTGATGA GCTGCGAGGA  
4681 GAGTCAGGTTT CTCAACAGCT GGGACTTGCC GCACCCGGTC GGGCCGTAGA TGACCCCGAT  
4741 GACGGGTGTC AGGTGGTAGT TCAAGGACAT GCAGCTGCCG TCGTCCCGGA GGAGGGGGGG  
4801 CACCTCGTTG AGCATGTCTC TAACTTGGAG GTTTTCCCGG ACGAGCTCGC CGAGGAGGCG  
4861 GTCCCGCCCC AGCGAGAGGA GCTCTTGCAG GGAAGCAAAG TTTTTCAGGG GCTTGAGTCC  
4921 GTCGGCCATG GGCATCTTGG CGAGGGTCTG CGAGAGGAGT TCGAGACGTC CCAGAGCTCG  
4981 GTGACGTGCT CTACGGCATC TCGATCCAGC AGACTTCCCT GTTTCGGGGG TTGGGACGAC  
5041 TGCGACTGTA GGGCACGAGA CGATGGGCGT CCAGCGCGGC CAGCGTCATG TCCTTCCAGG  
5101 GTCTCAGGTT CCGCGTGAGG GTGGTCTCCG TCACGGTGAA GGGGTGGGCC CCTGGCTGGG  
5161 CGCTTGCAAG GGTGCGCTG AGACTCATCC TGCTGGTGCT GAAACGGGCA CGGCTTTCGC  
5221 CCTGCGCGTC GCGGAGATAG CAGTTGACCA TGAGCTCGTA GTTGAGGGCC TCGGCGGCGT  
5281 GGCCCTTGGC GCGGAGCTTG CCCTTGGAAG AGCGTCCGCA GGCGGGACAG AGGAGGGATT  
5341 GCAGGGCGTA GAGCTTGGGC GCAAGAAAGA CCGACTCGGG AGCAAAAGCG TCCGCTCCGC  
5401 AGTGGGCGCA GACGGTCTCG CACTCGACGA GCCAGGTGAG CTCGGGCTGC TCGGGGTCAA  
5461 AAACCAAGTT TCCCCCGTTC TTTTGTATGC GCTTCTTACC TCGCGTCTCC ATGAGTCTGT  
5521 GTCCGCGCTC GGTGACAAAC AGGCTGTCCG TGTCCTCGTA GACGGACTTG ATTGGCTCTG  
5581 CCTGCAGGGG CGTCCCGCGG TCCTCCTCGT AGAGAAACTC GGACCACTCT GAGACAAAGG  
5641 CGCGCGTCCA CGCCAAGACA AAGGAGGCCA CGTGCAGGGG GTAGCGGTGCG TTGTCCACCA  
5701 GGGGGTCCAC CTTTTCCACC GTGTGCAGAC ACATGTCCCC TTCTCCGCA TCCAAGAAGG  
5761 TGATTGGCTT GTAGGTGTAG GCCACGTGAC CAGGGGTCCC CGACGGGGGG GTATAAAAGG  
5821 GGGCGGGTCT GTGCTCGTCC TCACTCTCTT CCGCTCGCT GTCCACGAGC GCCAGCTGTT  
5881 GGGGTAGGTA TTCCCTCTCG AGAGCGGGCA TGACCTCGGC ACTCAGGTTG TCAGTTTCTA  
5941 GAAACGAGGA GGATTGATG TTGGCTTGCC CTGCCGCAAT GCTTTTTAGG AGACTTTTAT  
6001 CCATCTGGTC AGAAAAGACT ATTTTTTTAT TGTCAAGCTT GGTGGCAAAG GAGCCATAGA  
6061 GGGCGTTGGA GAGAAGCTTG GCGATGGATC TCATGGTCTG ATTTTGTGTA CGGTCCGGCG  
6121 GCTCCTTGGC CGCGATGTTG AGCTGGACAT ATTGCGCGCG GACACACTTC CATTCGGGAA  
6181 AGACGGTGGT GCGCTCGTCC GGCACGATCC TGACGCGCCA GCCGCGGTTA TGCAGGGTGA  
6241 CCAGGTCCAC GCTGGTGGCC ACCTCGCCGC GCAGGGGCTC GTTAGTCCAG CAGAGTCTGC  
6301 CGCCCTTGGC CGAGCAGAAC GGGGGCAGCA CATCAAGCAG ATGCTCGTCA GGGGGGTCCG  
6361 CATCGATGTT GAAGATGCCG GGACAGAGTT TCTTGTCAA ATAGTCTATT TTTGAGGATG  
6421 CATCATCCAA GGCCATCTGC CACTCGCGGG CGGCCATTGC TCGCTCGTAG GGGTTGAGGG  
6481 GCGGACCCCA CGGCATGGGA TGCGTGAGGG CGGAGGCGTA CATGCCGATA ATGTCGTAAA  
6541 CATAGATGGG CTCCGAGAAG ATGCCGATGT TGGTGGGATA ACAGCGCCCC CCGCGGATGC  
6601 TGGCGCGCAC GTATTCATAC AACTCGTGCG AGGGGCCAAG AAGGCCGGGG CCGAAATTGG  
6661 TGCGCTGGGG CTGCTCGGCG CGGAAAACAA TCTGGCGAAA GATGGCGTGC GAGTTGGAGG  
6721 AGATGGTGGG CCGTTGGAAG ATGTTAAAGT GGGCGTGGGG CAAGCGGACC GAGTCGCGGA  
6781 TGAAGTGCGC GTAGGAGTCT TGCAGCTTGG CGACGAATC GCGGGTGACC AGAACGTCCA

6841 TGGCGCAGTA GTCCAGCGTT TCGCGGATGA TGTCATAACC CGCCTCTCCT TTCTTCTCCC  
6901 ACAGCTCGCG GTTGAGGGCG TATTCTCTGT CATCTTTCCA GTACTCCCGG AGCGGGAATC  
6961 CTCGATCGTC CGCACGGTAA GAGCCCAGCA TGTAAGAAATG GTTCACGGCC TTGTAGGGAC  
7021 AGCAGCCCTT CTCCACGGGG AGGGCGTAAG CTTGTGCGGC CTTGCGGAGC GAGGTGTGCG  
7081 TCAGGGCGAA GGTGTCCCTG ACCATGACTT TCAAGAACTG GTACTTGAAA TCCGAGTCGT  
7141 CGCAGCCGCC GTGCTCCCAT AGCTCGAAAT CGGTGCGCTT CTTGAGAGG GGGTTAGGCA  
7201 GAGCGAAAGT GACGTCATTG AAGAGAATCT TGCCTGCTCG CGGCATGAAA TTGCGGGTGA  
7261 TGCGGAAAGG GCCCGGGACG GAGGCTCGGT TGTGATGAC CTGGGCGGCG AGGACGATCT  
7321 CGTCGAAGCC GTTGATGTTG TGCCCGACGA TGTAAGATTG CATGAATCGC GGGCGGCCTT  
7381 TGATGTGCGG CAGCTTTTGT AGCTCCTCGT AGGTGAGGTC CTCGGGGCAT TGCAGGCCGT  
7441 GCTGCTCGAG CGCCATTCC TGGAGATGTG GGTGCGCTTG CATGAAGGAA GCCCAGAGCT  
7501 CGCGGGCCAT GAGGTCTGAG AGCTCGTCGC GAAAGAGGCG GAACCTGCTGG CCCACGGCCA  
7561 TCTTTTCGGG TGTGACGCAG TAGAAGGTGA GGGGGTCCCG CTCCCAGCGA TCCCAGCGTA  
7621 AGCGCGCGCG TAGATCGCGA GCAAGGGCGA CCAGCTCTGG GTCCCCCGAG AATTTTCATGA  
7681 CCAGCATGAA GGGGACGAGC TGCTTGCCGA AGGACCCCAT CCAGGTGTAG GTTTCTACAT  
7741 CGTAGGTGAC AAAGAGCCGC TCCGTGCGAG GATGAGAGCC GATTGGGAAG AACTGGATTT  
7801 CCTGCCACCA GTTGACGAGC TGGCTGTTGA TGTGATGAAA GTAGAAATCC CGCCGGCGAA  
7861 CCGAGCACTC GTGCTGATGC TTGTAAAAGC GTCCGCACTA CTCGACGCGC TGCACGGGCT  
7921 GTACCTCATC CACGAGATAC ACAGCGCGTC CCTTGAGGAG GAACCTCAGG AGTGGCGGCC  
7981 CTGGCTGGTG GTTTTCATGT TCGCCTGCGT GGGACTCACC CTGGGGCTCC TCGAGGACGG  
8041 AGAGGCTGAC GAGCCCGCGC GGGAGCCAGG TCCAGATCTC GGCGCGGCGG GGGCGGAGAG  
8101 CGAAGACGAG GCGCGCAGT TGGGAGCTGT CCATGGTGTG GCGGAGATCC AGGTCCGGGG  
8161 GCAGGGTTCT GAGGTTGACC TCGTAGAGGC GGGTGAGGGC GTGCTTGAGA TGCAGATGGT  
8221 ACTTGATTTT TACGGGTGAG TTGGTGCCCG TGTCCACGCA TTGCATGAGC CCGTAGCTGC  
8281 GCGGGGCCAC GACCGTGCCG CGGTGCGCTT TTAGAAGCGG TGTGCGGAC GCGCTCCCGG  
8341 CCGCAGCGGC GGTTCGGGCC CCGCGGCGAG GGGCGGCAGA GGCACGTCGG CGTGCGGCTC  
8401 GGGCAGGTCC CGGTGTTGCG CCTGAGAGC GCTGGCGTGC GCGACGACGC GGCGGTTGAC  
8461 ATCCTGGATC TGCCGCCTCT GCGTGAAGAC CACTGGCCCC GTGACTTTGA ACCTGAAAGA  
8521 CAGTTCAACA GAATCAATCT CGGCGTCATT GACGGCGGGC TGACGCAGGA TCTCTTGAC  
8581 GTCGCGCGAG TTGTCTGGT AGGCGATCTC GGACATGAAC TGCTCGATCT CCTCGATCTG  
8641 GAGATCGCCG CGACCCGCGC GCTCCACGGT GCGGCGGAGG TCATTTCGAGA TGCAGCCCAT  
8701 GAGCTGCGAG AAGGCGCCCA GGCGGCTCTC GTTCCAGACG CGGCTGTAGA CCACGTCCCC  
8761 GTCGCGGTCG CGCGCGCGCA TGACCACCTG CGCGAGGTTG AGCTCCACGT GCCGCGCGAA  
8821 GACGGCGTAG TTGCGCAGGC GCTGGAAGAG GTAGTTGAGG GTGGTGGCGA TGTGCTCGGT  
8881 GACGAAGAAG TACATGATCC AGCGGCGCAG GGGCATCTCG CTGATGTGCG CGATGGCCTC  
8941 CAGCCTTTTC ATGGCCTCGT AGAAATCCAC GGCGAAGTTG AAAAAGTGGG CGTTGCGGGC  
9001 CGAGACCGTG AGCTCGTCTT GATGAGCTCG GCGATGGTGG CCGCATGCTC  
9061 GCGCTCGAAA TCCCCGGGGG CCTCGTCTCT TTCTCTTTCT TCCATGACAA CCTCTTCTAT  
9121 TTCTTCTCTT GGGGGCGGTG GTGGTGCGGG GGCCCGACGA CGACGGCGAC GCACCGGGAG  
9181 ACGGTCGACG AAGCGCTCGA TCATCTCCCC GCGGCGGCGA CGCATGGTTT CCGTGACGGC  
9241 GCGACCCCGT TCGCGAGGAC GCAGCGTGAA GACGCCCGCG GTCATCTCCC GGTAAATGGG  
9301 CCGGTCCCCG TTGGGCAGCG AGAGGGCGCT GACGATGCAT CTTATCAATT GCGGTGTAGG  
9361 GGACGTGAGC GCGTCGAGAT CGACCGGATC GGAGAATCTT TCGAGGAAAG CGTCTAGCCA  
9421 ATCGCAGTCG CAAGGTAAGC TCAAAACAGT AGCAGCCCTG TGGACGCTGT TAGAATTGCG  
9481 GTTGCTAATG ATGTAATTGA AGTAGGCGTT TTTGAGGCGG CGGATGGTGG CGAGGAGGAC  
9541 CAGGTCTTTG GGTCCCCTT GCTGGATGCG GAGCCGCTCG GCCATGCCCC AGGCCTGGCC  
9601 CTGACACCGG CTTAGGTTCT TGTAGTAGTC ATGCATGAGC CTCTCGATGT CATCACTGGC  
9661 GGAGGCGGAG TCTTCCATGC GGGTGACCCC GACGCCCTG AGCGGCTGCA CGAGCGCCAG  
9721 GTCGCGGACG ACGCGCTCGG CGAGGATGGC CTGTGACAG CCGGTGAGGG TGTCTGGAA  
9781 GTCGTCCATG TCGACGAAGC GGTGGTAGGC CCTGTGTTG ATGGTGTAAG TGCAGTTGGC  
9841 CATGACGCGC CAGTTGACGG TCTGCAGGCC GGGCTGCACG ACCTCGGAGT ACCTGAGCCG  
9901 CGAGAAGGCG CGCGAGTCGA AGACGTAGTC GTTGACGCTG CGCACAAGGT ACTGGTATCC  
9961 GACTAGGAAG TGCGGCGGCG GCTGGCGGTA GAGCGGCCAG CGCTGGGTGG CCGGCGCGCC  
10021 CCGGGCCAGG TCCTCGAGCA TGAGGCGGTG GTAGCCGTAG AGGTAGCGGG ACATCCAGGT  
10081 GATGCCGGCA GCGGTGTTGG AGGCGCGCGG GAACTCGCGG ACGCGGTTCC AGATGTTGCG  
10141 CAGCGGCAGG AAATAGTCCA TGGTCCGCGC GGTCTGGCCG GTGAGACGCG CCAGTCATT  
10201 GACGCTCTAG AGGCAAAAAC GAAAGCGGTT GAGCGGGCTC TTCTTCCGTA GCCTGGCGGA



10261 ACGCAAACGG GTTAGGCCGC GCGTGTACCC CCGTTCGAGT CCCCTCGAAT CAGGCTGGAG  
10321 CCGCGACTAA CGTGGTATTG GCACTCCCGT CTCGACCCGA GCCCGATAGC CGCCAGGATA  
10381 CCGCGGAAGA GCCCTTTTTC CCGGCCGARG GGAGTCGCTA GACTTGAAAG CGGCCGAAAA  
10441 CCCCCCGGG TAGTGGCTCG CGCCCGTAGT CTGGAGAAGC ATCGCCAGGG TTGAGTCGCG  
10501 GCAGAACCCG GTTCGCGGAC GGCCGCGGCG AGCGGGACTT GGTACCCCCG CCGATTAAAA  
10561 GACCCACAGC CAGCCGACTT CTCCAGTTAC GGGAGCGAGC CCCCTTTTTT CTTTTTGCCA  
10621 GATGCATCCC GTCTGCGCC AAATGCGTCC CACCCCCCG GCGACCACCG CGACCCGCGC  
10681 CGTAGCAGGC GCCGGCGCTA GCCAGCCACA GCCACAGACA GAGATGGACT TGGGAAGAGG  
10741 CGAAGGGCTG GCGAGACTGG GGGCGCCTTC CCCGGAGCGA CACCCCCCGG TGCAGCTGCA  
10801 GAAGGACGTG CGCCCGCGCT ACGTGCCTGC GCAAAACCTG TTCAGGGACC GCAGCGGGGA  
10861 GGAGCCCGAG GAGATGCGCG ACTGCCGTT TCGGGCGGGC AGGGAGCTGC GCGAGGGCCT  
10921 GGACCGCCAG CGCGTGCTGC GCGACGAGGA TTTCGAGCCG AACGAGCAGA CGGGGATCAG  
10981 CCGCGCGCGC GCGCAGTGG CGGCGGCCAA CCTGGTGACG GCCTACGAGC AGACGGTGAA  
11041 GCAGGAGCGC AACTTCCAAA AGAGTTTCAA CAACCATGTG CGCACCTGA TCGCCGCGCA  
11101 GGAGGTGGCC CTGGGCCTGA TGCACCTGTG GGACCTGGCG GAGGCCATCG TGCAGAACCC  
11161 GGACAGCAAG CCTCTGACGG CGCAGCTGTT CCTGGTGGTA CAGCACAGCA GGGACAACGA  
11221 GCGTTCAGG GAGGCGCTGC TAAACATCGC CGAGCCCGAG GGTGCTGGC TGCTGGAGCT  
11281 GATCAACATC TTGCAGAGCA TCGTAGTTCA GGAGCGCAGC CTGAGCTTG CCGAGAAGGT  
11341 GCGCGCAATC AACTACTCGG TGCTTAGCCT GGGCAAGTTT TACGCGCGCA AGATTTACAA  
11401 GACGCCGTAC GTGCCCATAG ACAAGGAGGT GAAGATAGAC AGCTTTTACA TGCGCATGGC  
11461 GCTCAAGGTG CTGACGCTGA GCGACGACCT GGGCGTGAC CGCAACGACC GCATCCACAA  
11521 GGCGGTGAGC GCGAGCCGGC GGCGCGAGCT GAGCGACCGC GAGCTGATGC TGAGCTGCG  
11581 CCGGGCGCTG GTAGGGGGCG CCGCCGCGCG CGAGGAGTCY TACTTCGACA TGGGGGCGGA  
11641 CCTGCATTGG CAGCCGAGCC GGCGCGCCTT GGAGGCCGCC TACGGTCCAG AGGACTTGGA  
11701 TGAGGAAGAG GAAGAGGAGG AGGATGCACC CGCTGCGGGG TACTGACGCC TCCGTGATGT  
11761 GTTTTTAGAT GCAGCAAGCC CCGGACCCCG CCATAAGGGC GGCGCTGCAA AGCCAGCCGT  
11821 CCGGTCTAGC ATCGGACGAC TGGGAGGCTG CGATGCAACG CATCATGGCC CTGACGACCC  
11881 GCAACCCCGA GTCCTTTAGA CAACAGCCCG AGGCCAACAG ACTCTCGGCC ATTCTGGAGG  
11941 CGGTGCTCCC TTCTCGGACC AACCCACGCG ACGAGAAGGT GCTGGCGATC GTGGCGGACC  
12001 TGGCGGAGAA CAAGGCCATC CGTCCCGACG AGGCCGGGCT AGTGTAACA GCCCTGCTGG  
12061 AGCGCGTAGG CCGCTACAAC AGCACAACG TGCAGTCAA CCTGGACCGG CTGGTGACGG  
12121 ACGTGCAGCA AGCCGTGGCG CAGCGCGAGC GGTTCAAGAA CGAGGGCCTG GGCTCGCTGG  
12181 TGGCGCTGAA CGCCTTCCTG GCGACGCGC CGGCGAACGT GCCGCGCGGG CAGGATGATT  
12241 ACACCAACTT TATCAGCGCG CTGCGGCTGA TGGTGACCGA GGTGCCCGAG AGCGAGGTGT  
12301 ACCAGTCGGG CCCGACTAC TTTTCCCAA CTAGCAGACA GGGCCTGCAA ACGGTGAACC  
12361 TGAGCCAGGC TTTCAAGAAC CTGCGCGGGC TGTGGGGCGT GCAGGCGCCC GTGGCGGACC  
12421 GGTGACGGT GAGCAGCTTG CTGACGCCCA ACTCGCGGCT GCTGCTGCTG CTGATCGCGC  
12481 CCTTCACCGA CAGTGGCAGC GTAAACCGCA ACTCGTACCT GGGTCACCTG CTAACGCTGT  
12541 ACCGCGAGGC CATAGGCCAG GCGCAGGTGG ACGAGCAGAC CTTCCAGGAG ATCACTAGCG  
12601 TGAGCCGCGC GCTGGGGCAG AACGACACCG ACAGTCTGAG GGCCACCCTG AACTTCTTGC  
12661 TGACCAATAG ACAGCAGAAG ATCCCGGCGC AGTACGCGCT GTCGGCCGAG GAGGAGCGCA  
12721 TCCTGAGATA TGTGCAGCAG AGCGTAGGGC TTTTCTGAT GCAGGAGGGG GCCACTCCCA  
12781 GCGCCGCGCT GGACATGACC GCGCGCAACA TGGAACTAG CATGTACGCC GCCAACCAGC  
12841 CGTTTATCAA TAAGCTAATG GACTACCTGC ATCGCGCGGC GTCCATGAAC TCGGACTACT  
12901 TTACCAATGC CATTTTGAAC CCGCACTGGC TTCCGCGGCC GGGGTTCTAT ACGGGCGAGT  
12961 ACGACATGCC CGACCCCAAC GACGGGTTTT TGTGGGACGA CGTGGACAGC GCGGTGTTTT  
13021 CACCGACCTT GCAAAAGCGC CAGGAGGCGG TCGCACGCC CGCGAGCGAG GGCGCGGTGG  
13081 GTCGGAGCCC CTTTCTTAGC TTAGGGAGTT TGCATAGCTT GCCGGGCTCT GTGAACAGCG  
13141 GCAGGGTGAG CCGGCCGCGC TTGCTGGGCG AGGACGAGTA CCTGAACGAC TCGCTGCTGC  
13201 AGCCGCGCGG GGTCAAGAAC GCCATGGCCA ATAACGGGAT AGAGAGTCTG GTGGACAAC  
13261 TGAACCGCTG GAAGACCTAC GCTCAGGACC ATAGGGAGCC TGCGCCCGCG CGCGCGGAC  
13321 AGCGCCACGA CCGGCAGCGG GGCTTGGTGT GGGACGACGA GGACTCGGCC CCGATAGCA  
13381 GCGTGTGGGA CTGGGGCGGG AGCGGTGGGG TCAACCCGAT ATCGCGCATC CTGCAGCCCA  
13441 AACTGGGGCG ACGGATGTTT TGAATGCAAA ATAAACTCA CCAAGGCCAT AGCGTGCGTT  
13501 CTCTTCTTG TTAGAGATGA GCGTGCCTG GGTGTCTTCC TCTCCTCTC CCTCGTACGA  
13561 GAGCGTGATG GCGCAGGCGA CCCTGGAGGT TCCGTTTGTG CTTCCGCGGT ATATGGCTCC  
13621 TACGGAGGGC AGAAACAGCA TTCGTTACTC GGAGCTGGCT CCGTTGTACG ACACCACTCG

13681 CGTGTACTTG GTGGACAACA AGTCGGCGGA CATCGCTTCC CTGAACTATC AAAACGACCA  
13741 CAGCAACTTC CTGACCACGG TGGTGCAGAA CAACGATTTC ACCCCCGCCG AGGCTAGCAC  
13801 GCAGACGATA AATTTTGACG AGCGGTGCGG GTGGGGCGGT GATCTGAAGA CCATTCTGCA  
13861 CACCAACATG CCCAATGTGA ACGAGTACAT GTTCACCAGC AAGTTTAAGG CGCGGGTGAT  
13921 GGTGGCTAGA AAACACCCAC AGGGGGTAGA AGCAACAGAT TTAAGCAAGG ATATCTTAGA  
13981 GTATGAGTGG TTTGAGTTTA CCCTGCCCCG GGGCAACTTT TCCGAGACCA TGACCATAGA  
14041 CCTGATGAAC AACGCCATCT TGGAAAACTA CTTGCAAGTG GGGCGGCAAA ATGGCGTGCT  
14101 GGAGAGCGAT ATTGGAGTCA AGTTTGACAG CAGAAATTTC AAGCTGGGCT GGGACCCGT  
14161 GACCAAGCTG GTGATGCCAG GGGTCTACAC CTACGAGGCC TTTCACCCGG ACGTGGTGCT  
14221 GCTGCCGGGC TCGGGGGTGG ACTTCACAGA GAGCCGCTG AGCAACCTCC TGGGCATTCG  
14281 CAAGAAGCAA CCTTTCCAAG AGGGCTTCAG AATCATGTAT GAGGATCTAG AAGGGGCAAA  
14341 CATCCCCGCC CTGCTGGATG TGCCCAAGTA CTTGGAAAGC AAGAAGAAGT TAGAGGAGGC  
14401 ATTGAGAGAAT GCTGCTAAAG CTAATGGTCC TGCAAGAGGA GACAGTAGCG TCTCAAGAGA  
14461 GGTGAAAG GCAGCTGAAA AAGAATTGT TATTGAGCCC ATCAAGCAAG ATGATACCAA  
14521 GAGAAATTAC AACCTCATCG AGGGAACCAT GGACACGCTG TACCGCAGCT GGTACCTGTC  
14581 CTATACCTAC CGGGACCCTG AGAACGGGGT GCAGTCGTGG ACGCTGCTCA CCACCCCGGA  
14641 CGTCACCTGC GCGCGGAGC AAGTCTACTG GTCGCTGCCG GACCTCATGC AAGACCCGT  
14701 CACCTTCCGT TCTACCCAGC AAGTCAGCAA CTACCCCGTG GTCGGCGCCG AGCTCATGCC  
14761 CTTCCGCGCC AAGAGCTTTT ACAACGACCT CGCCGTCTAC TCCCAGCTCA TCCGCAGCTA  
14821 CACCTCCCTC ACCCACGTCT TCAACCGCTT CCCCACAAC CAGATCCTCT GCCGTCCGCC  
14881 CGCGCCACC ATCACCACC TCAGTGA AAA CGTGCTGCT CTCACAGATC ACGGGACGCT  
14941 ACCGCTGCGC AGCAGTATCC GCGGAGTCCA GCGAGTGACC GTCACTGACG CCCGTGCGCG  
15001 CACCTGTCCC TACGTCTACA AGGCCCTGGG CATAGTCGCG CCGCGTGTGC TTTCCAGTCG  
15061 CACCTTCTAA AAAATGTCTA TTCTCATCTC GCCCAGCAAT AACACCGGCT GGGGTATTAC  
15121 TAGGCCCAGC AGCATGTACG GAGGAGCCAA GAAACGTCCC AGCAGCACC CGTCCGCGTC  
15181 CGCGGCCACT TCCGCGCTCC GTGGGGCGCT TACAAGCGCG GGCGGACTGC CACCGCCGCC  
15241 GCCGTGCGCA CCACCGTCGA CGACGTCATC GACTCGGTGG TCGCCGACGC GCGCAACTAT  
15301 ACTCCCGCCC CTTGACCGT GGACGCGGTT CATTGACAGC GTGGTGCGGA CGCGCGGCG  
15361 ATATGACGAG CGCAAGAGCC GCGGAGCCGA CGGATCGCCC AGGCGCCAT CGGAGCAGC  
15421 CCGCCATGGG GCGCCGCCCC AGCTCTGTG GCGCGGCCA GACGACGCG CCGCGGGCC  
15481 ATGATGCGAG CCGCGCGCCG CGCCGCCACT GCACCCCGC CAGGCAGGAC TCGCAGACGA  
15541 GCGGCCGCGC CCGCGCGCGC GGCCATCTCT AGCATGACCA GACCCAGGCG CGGAAACGTG  
15601 TACTGGGTGC GCGACTCCGT CACGGGCGTG CCGGTGCCCC TGCGCACCCG TCCTCCTCGT  
15661 CCTGATCTA ATGCTTGTGT CCTCCCCCGC AAGCGACGAT GTCAAAGCGC ATCTACAAGA  
15721 GAGATGCTCC AGGTGCTCGC CCCGGAGATT TACGGACCAC CCCAGGCGGA CCAGAAACCC  
15781 CGCAAAATCA AGCGGGTTAA AAAAAAGGAT GAGGTGGACG AGGGGGCAGT AGAGTTTGTG  
15841 CGCGAGTTCC CTCGCGGCG GCGCGTAAAT TGGAAAGGGC GCAGGTGCAC CGGTGTTGCG  
15901 GCGCGGCACG GCGGTGGTGT TCACGCCCGG CGAGCGGTCC TCGGTACAGGA GCAAGCGTAG  
15961 CTATGACGAG GTGTACGGCG ACGACGACAT CCTGGACCAG GCGGCAGAGC GGGCGGGCGA  
16021 GTTTGCCTAC GGAAGCGGT CGCGCGAAGA GGAGCTGATC TCGCTGCCCG TGGACGAGAG  
16081 CAATCCCACG CCGAGCCTGA AGCCCGTGAC CTGCAGCAGG TGCTGCCCCA GCGGTTGCTG  
16141 CTGCCGAGCC GCGGGATCAA GCGCGAGGGC GAGAACATGT ACCCGACCAT GCAGATCATG  
16201 GTGCCAAAGC GCGGCGCGT GGAGGAAGTG CTGGACACCG TGAATATGGA TGTGGAGCCC  
16261 GAGGTCAAGG TCGCGCCCAT CAAGCAGGTG GCGCGGGCC TGGCGGTGCA GACCGTGGAC  
16321 ATTCAGATCC CCACCGACAT GGATGTCGAC AAAAAACCTT CGACCGACAT CGAGGTGCAG  
16381 ACCGACCCCT GGCTCCCAGC CTCACCGCT ACCGCTTCCA CTTCTACCGT CGCCACGGTC  
16441 ACCGAGCCTC CCAGGAGGCG AAGATGGGGC CCCGCCAACC GGCTGATGCC CAACTACGTG  
16501 TTGCATCCTT CCATTATCCC GACGCCGGG TACCGCGGCA CCCGGTACTA CGCCAGCCGC  
16561 AGGCGCCCAG CCAGCAAACG CCGCGCCGC ACCGCCACCC GCGCGCTCT GCCCCCCGCC  
16621 CGCGTGCGCC GCGTAACCAA CCGCGCGGG CCGCTCGCTC GTTCTGCCA CCGTGCCTA  
16681 CCACCCAGC ATCCTTTAAT CCGTGTGCTG TGATACTGTT GCAGAGAGAT GGCTTCACT  
16741 TGCCCGCTGC GCATCCCGT TCCGAATTAC CGAGGAAGAT CCCGCCGAG GAGAGCCATG  
16801 GCAGGCAGCG GCCTGAACCG CCGCGGCGG CCGGCCATGC GCAGGCGCCT GAGTGGCGGC  
16861 TTTCTGCCCG CGCTCATCCC CATAATCGCG GCGGCCATCG GCACGATCCC GGGCATAGCT  
16921 TCCGTGCGC TGCAGGCGTC GCAGCGCGT TGATGTGCGA ATAAAGCCTC TTTAGACTCT  
16981 GACACACCTG GTCCTGTATA TTTTAGAAT GGAAGACATC AATTTTGCCT CCCTGGCTCC  
17041 GCGGCACGGC ACGCGGCCGT TCATGGGCAC CTGGAACGAG ATCGGCACCA GCCAGCTGAA

17101 CGGGGGCGCC TTCAATTGGA GCAGTGTCTG GAGCGGGCTT AAAAATTTG GCTCGACGCT  
17161 CCGGACCTAT GGGAAACAAGG CCTGGAATAG TAGCACGGGG CAGTTGTTGA GGGAAAAGCT  
17221 CAAAGACCAG AACTTCCAGC AGAAGGTGGT GGACGGCCTG GCCTCGGGCA TTAACGGGGT  
17281 GGTGGACATC GCGAACCAGG CAGTGCAGCG CGAGATAAAC AGCCGTCTGG ACCCGCGGCC  
17341 GCCCACGGTG GTGGAGATGG AAGATGCAAC TCTTCCGCCG CCGAAGGGCG AGAAGCGGCC  
17401 GCGGCCAGAT GCGGAGGAGA CGATCCTGCA GGTGGACGAG CCGCCTTCGT ACGAGGAGGC  
17461 CGTGAAGGCC GGCATGCCCA CCACGCGCAT CATCGCGCCA CTGGCCACGG GTGTAATGAA  
17521 ACCCGCCACC CTTGACCTGC CTCACCACC CACGCCCCTG CCACCGAAGG CAGCTCCGGT  
17581 TGTGCAGCCC CCTCCGGTGG CGACCGCCGT GCGCCGCGTC CCCGCCCGCC GCCAGGCCCA  
17641 GAACTGGCAG AGCACGCTGC ACAGTATTGT GGGCCTGGGA GTGAAAAGTC TGAAGCGCCG  
17701 CCGATGCTAT TGAGAGAGAG GAAGGAGGAC ACTAAAGGGA GAGCTTAACT TGTATGTGCC  
17761 TTACCGCCAG AGAACGCGCG AAGATGGCCA CCCCCTCGAT GATGCCCGAG TGGGCGTACA  
17821 TGCACATCGC CGGSCAGGAC GCCTCGGAGT ACCTGAGCCC GGGTCTGGTG CAGTTTGCCC  
17881 GCGCCACCGA CACGTACTTC AGCCTGGGCA ACAAGTTTAG GAACCCACAG GTGGCCCCGA  
17941 CCCACGATGT GACCACGGAC CAGTCCCAGC GTCTGACGCT GCGCTTTGTG CCCGTGGATC  
18001 GCGAGGACAC CAGTACTCGT CGAAGGCGCG CTTCACTCTG GCCGTGGGCG ACAACCGGGT  
18061 GCTAGACATG GCCAGCACGT ACTTTGACAT CCGCGGCGTC CTGGACCGCG GTCCCAGTTT  
18121 CAAACCCTAC TCGGGCACGG CTTACAACAG CCTTGCCCCC AAGGGCGCTC CCAATCCAG  
18181 TCAGTGGGTT GCCAAAGAAA ATGGTCAGGG AACTGATAAG ACACATACTT ATGGCTCAGC  
18241 TGCCATGGGA GGAAGCAACA TCACCATTGA AGGTTTAGTA ATTGGAACATG ATGAAAAAGC  
18301 TGAGGATGGC AAAAAAGATA TTTTGTGCAA TAACTTTAT CAGCCAGAAC CTCAAGTAGG  
18361 TGAAGAAAAC TGGCAAGAGT CTGAAGCCTT CTATGGAGGC AGAGCTCTTA AGAAAGACAC  
18421 AAAAATGAAG CCCTGCTATG GCTCATTTCG AAGACCTACC AATGAAAAAG CCGGACAAGC  
18481 TAAATTTAAG CCAGTGGAAG AGGGGCAGCA ACCTAAAGAT TATGACATAG ATTTGGCTTT  
18541 CTTTGACACA CCTGGAGGCA CCATCACAGG AGGCACAGAC GAAGAATATA AAGCAGACAT  
18601 TGTGTTGTAC ACTGAAAATG TCAACCTTGA AACCCACAGC ACCCACGTGG TATACAAGCC  
18661 AGGAAAAGAG GATGACAGTT CAGAAGTAAA TTTGACACAG CAGTCCATGC CCAACAGGCC  
18721 TAACTACATT GGCTTCAGAG ACAACTTTGT GGGACTCATG TACTACAACA GTACTGGCAA  
18781 CATGGGTGTG CTGGCTGGTC AGGCCTCTCA ATTGAATGCT GTGGTCGACT TGCAAGACAG  
18841 AAACACCGAG CTGTCTTACC AGCTCTTGCT AGATTCTCTG GGTGACAGAA TCAATACTT  
18901 CGCCGATGGG AACTCTGCGG TGGATGACAA TGATCCAGAT GTCAGGATCA TTGAAAATCA  
18961 TGGTGTGGAA GATGAACTTC CAACTATTG CTTCCCATTG AATGGCACTG GCACCAATTC  
19021 AACATATCTT GCGGTAAAGG TGAAACCAGA TCAAGATGGT GATGTTGAAA GCGAGTGGGA  
19081 TAAAGATGAT ACCATTGCAA GGCAGAAATCA AATCGCCAAG GGCAACGTCT TTGCCATGGA  
19141 GATCAACCTC CAGGCCAACC TGTGGAAGAG TTTTCTGTAC TCGAACGTGG CTTGTACCT  
19201 GCCCAGCTCC TACAAGTACA CGCCGGCCAA TGTTACGCTG CCCGCCAACA CCAACACCTA  
19261 CGAGTACATG AACGGCCGCG TGGTAGCCCC CTCGCTGGTG GACGCTTACA TCAACATAGG  
19321 CGCCGATGGG TCGCTGGACC CCATGGACAA CGTCAACCCC TTCAACCACC ACCGCAATGC  
19381 GGGCCTGCGC TACCGCTCCA TGCTTCTGGG CAACGGCCGC TACGTGCCCT TCCACATCCA  
19441 AGTGCCCCAA AAGTTCTTTG CCATCAAGAA CCTGCTCCTG CTCCCGGGCT CCTACACCTA  
19501 CGAGTGGAAC TTCCGCAAGG ATGTCAACAT GATCCTGCAG AGTTCCCTCG GCAACGACCT  
19561 GCGCGTCGAC GCGCCTCCG TCCGCTTCGA CAGCGTCAAC CTCTACGCCA CTTTCTTCCC  
19621 CATGGCGCAC AACACCGCCT CCACCCTGGA AGCCATGCTG CGCAACGACA CCAACGACCA  
19681 GTCCTTCAAC GACTACCTCT CGGCCGCCAA CATGCTCTAC CCCATCCCGG CCAAGGCCAC  
19741 CAACGTGCCC ATCTCCATCC CCTCGCGCAA CTGGGCGGCT TTTGCGGGCT GGAGTTTCAC  
19801 CCGTCTGAAA ACCAAGGAAA CTCCCTCCCT CGGCTCGGGT TTTGACCCCT ACTTTGTCTA  
19861 CTCGGGCTCG ATCCCTTACC TTGACGGACC CTTTACCTT AACCACACCT TCAAGAAAGT  
19921 CTCCATCATG TTGACTCCT CGGTACGCTG GCCCAGCAAC GACCGGCTGC TCACGCCGAA  
19981 CGAGTTCGAG ATCAAGCGCA GCGTCGACGG GGAAGGCTAC AACGTGGCCC AATGCAACAT  
20041 GACCAAGGAC TGGTTCCTCG TCCAGATGCT CTCCCCTAC AACATCGGCT ACCAGGGCTT  
20101 CCACGTGCCC GAGGGCTACA AGGACCGCAT GTACTCCTTC TTCCGCAAT TCCAGCCCAT  
20161 GAGCAGGACG GTGGTCGATG AGATCAACTA CAAGGACTAC AAGGCCGTCA CCTGCCCTT  
20221 CACGACCAAC AACTCGGGCT TCACCGGCTA CCTTGACCCC ACCATGCGCC AAGGGCAGCC  
20281 CTACCCCGCC AACTTCCCTT ACCCGCTCAT CGGCCAGACA GCCGTGCCAT CCGTCACCCA  
20341 GAAAAGTCTC CTCTGCGACA GGGTCATGTG GCGCATCCCC TTCTCCAGCA ACTTCATGTC  
20401 CATGGGCGCC TTCACCGACC TGGGTAGAAA CATGTTCTAC GCCAACTCGG CCCACGCGCT  
20461 CGACATGACC TTCGAGGTGG ACCCCATGGA TGAGCCACC GTCTCTTATC TTCTCTTCGA

20521 AGTGTTTCGAC GTGGTCAGAG TGCACCAGCC GCACCGCGGC GTCATCGAGG CCGTCTACCT  
 20581 GCGCACGCCG TTCTCCGCCG GAAACGCCAC CACCTAAGCA TGAGCGGCTC CAGCGAAAGA  
 20641 GAGCTCGCGT CCATCGTGCG CGACCTGGGC TGCGGGCCTA CTTTTTGGGC ACCCACGACA  
 20701 CAGCGATTCC CGGGCTTTCT TGCCGGCGAC AAGCTGGCCT GCGCCATTGT CAACACGGCC  
 20761 GGCCGCGAGA CCGGAGGCGT GCACTGGCTC GCCTTCGGCT GGAACCCGCG CTCGCGCACC  
 20821 TGCTACATGT TCGACCCCTT TGGGTCTCTG GACCGCCGGC TCAAGCAGAT TTACAGCTTC  
 20881 GAGTACGAGG CCATGCTGCG CCGAAGCGCC GTGGCCTCTT CGCCCGACCG CTGTCTCAGC  
 20941 CTCGAACAGT CCACCCAGAC CGTGCAGGGG CCCGACTCCG CCGCCTGCGG ACTTTCTGT  
 21001 TGCATGTTCT TGCATGCCCT CGTGCCTGCG CCCGACCGAC CCATGGACGG GAACCCCAACC  
 21061 ATGAACTTGC TGACGGGGGT GCCCAACGGC ATGCTACAAT CGCCACAGGT GCTGCCCAACC  
 21121 CTCAGGCGCA ACCAGGAGGA GCTCTATCGC TTCTTCGCGC GCCACTCCCC TTACTTTTCGC  
 21181 TCCCAACGCG CGGCCATCGA ACACGCCACC GCTTTTGACA AAATGAAACA ACTGCGTGTA  
 21241 TCTCAATAAA CAGCACTTTT ATTTTACATG CACTGGAATA TATGCAAGTT ATTTAAAAGT  
 21301 CGAAGGGGTT CTCGCGCTCA TCCTTGTGCG CCGCGCTGGG GAGGGCCACG TTGCGGTACT  
 21361 GGTGACTGGG CTGCCACTTG AACTGCAGGG TACCACTTTT GGGCCTGGG GTCTCGGGGA  
 21421 AGGTCTCGCT CCACATACGC CGGCTCATCT GCAGGGCGCC CAGCATGTCC GGGGCGGATA  
 21481 TCTTGAAATC GCAGTTGGGA CCGGTGCTCT GCGCGCGCGA GTTGCGGTAC ACGGGGTTGC  
 21541 AGCACTGGAA CACCATCAGA CTGGGGTACT TTACGCTGGC CAGCACGCTC TTGTCGCTGA  
 21601 TCTGATCCTT GTCCAGATCC TCGGCGTTGC TCACGCCGAA TGGGGTCATC TTGCACAGTT  
 21661 GGCGACCCAG GAATGGCACG CTCTGAGGCT TGTGGTTACA CTCGCAGTGC ACGGGCATCA  
 21721 GCATCATCCC CGCGCCGCGC TGCATATTCG GGTAGAGGCC TTGACAAAGG CCGTGATCTG  
 21781 CTTGAAAGCT TGTGGGCTT TGGCCCCCTC GCTGAAAAAC AGGCCGCGAG TCTTCCCCTG  
 21841 GAACTGGTTA TTCCCGCAAC CGGCATCCTG CACGCAGCAG CGCGCGTCACT GGTCTGTCAG  
 21901 TTGCACCACG CTTCTTCCCC AGCGGTTCTG GGTACCTTGG GCTTTGCTGG GTTGCTCCTT  
 21961 CAACGCGCGC TGCCCGTTCT CGCTGGTCAC ATCCATCTCC ACCACGTGGT CTTGTGCGAT  
 22021 CATCACCGTT CCATGCAGAC ACTTGAGCTG GCCTTCCACC TCGGTGCAGC CGTGATCCCA  
 22081 CAGGGCACTG CCGGTGCACT CCCAGTTCTT GTGCGCGATC CCGCTGTGGC TGAAGATGTA  
 22141 ACCTTGCAAG AGGCGACCCA TGATGGTGCT AAAGCTCTTC TGGGTGGTGA AGGTAGTTG  
 22201 CAGACCGCGG GCCTCCTCGT TCATCCAGST CTGGCACATC TTTTGGAAGA TCTCGGCTG  
 22261 CTCGGGCGTG AGCTGTAAAG CATCGCGCAG GCCGCTGTG ACGCGGTAAC GTTCCATCAG  
 22321 CACGTTTCATG GTATCCATGC CCTTTTCCCA GGACGAGACC AGAGGCAGAC TCAGGGGGTT  
 22381 GCGCACGTTT AGGACACCGG GGGTCKCGGG CTCGACGATA CGTTTTCCGT CTTGCGCTTC  
 22441 CTTCAACAGA ACCGGAGGCT GGCTGAATCC CACTCCCAACA ATCACGGCAT CTTCTTGGGG  
 22501 CATCTCTTCG TCGGGGTCTA CCTTGGTCAC ATGCTTGGTC TTTCTGGCTT GCTTCTTTTT  
 22561 TGGAGGGCTG TCCACGGGGA CCACGTCTCT TCGGAAGACC CGGAGCCAC CCGCTGATAC  
 22621 TTTCGGCGCT TGGTGGGCG AGGAGGTGGC GCGCGCGAGG GGCTCCTCTC GTGCTCCGGC  
 22681 GGATAGCGCG CCGACCCGTG GCCCGGGGCG GGAGTGCCCT CTCGCTCCAT GAACCGGCGC  
 22741 ACGTCTGACT GCCGCCGGCC ATTGTTTCTT AGGGGAAGAT GGAGGAGCAG CCGCGTAAGC  
 22801 AGGAGCAGGA GGAGGACTTA ACCACCCACG AGCAACCCAA AATCGAGCAG GACCTGGGCT  
 22861 TCGAAGAGCC GGCTCGTCTA GAACCCACA GGATGAACAG GAGCACGAGC AAGACGCAGG  
 22921 CCAGGAGGAG ACCGACGCTG GGCTCGAGCA TGGCTACCTG GGAGGAGAGG AGGATGTGCT  
 22981 GCTGAAACAC CTGCAGCGCC AGTCCCTCAT CCTCCGGGAC GCCCTGGCCG ACCGGAGCGA  
 23041 AACCCTCTCT AGCGTCGAGG AGCTGTGTCT GGCCTACGAG CTCAACCTCT TCTCGCCGCG  
 23101 CGTGCCCCCT AAACGCCAGC CCAACGGCAC CTGCGAGCCC AACCCTGCTC TCAACTTCTA  
 23161 TCCCGTCTTT GCGGTCCCCG AGGCCCTTGC CACCTATCAC ATCTTTTTC AAGAACAAAA  
 23221 GATCCCCGTC TCCTGCCGCG CCAACCGCAC CCGCGCCGAC GCGCTCCTCG CTCTGGGGCC  
 23281 CGGCGCGCGC ATACCTGATA TTGCTTCCCT GGAAGAGTGC CCAAAATCTT CGAAGGGCTC  
 23341 GGTCGGGACG AGACGCGCGC GCGGAAACGC TCTGAAAGAA ACAGCAGAGG AAGAGGGTCA  
 23401 CACTAGCGCC CTGGTAGAGT TGGAAAGCGA CAACGCCAGG CTGGCCGTGC TCAAGCGCAG  
 23461 CGTTGAGCTC ACCCACTTCG CCTACCCCGC CGTCAACCTC CCGCCCAAGC TCATGCGTCG  
 23521 CATCATGGAT CAGCTAATCA TGCCCCACAT CGAGGCCCTC GATGAAAGTC AGGAGCAGCG  
 23581 CCCCAGGAGC ACCCGGCCCG TGGTCAGCGA TGAGCAGCTT GCGCGCTGGC TTGGTACCCG  
 23641 CGACCCCCAG GCCCTGGAGC AGCGGCGCAA GCTCATGCTG GCCGTGGTCC TGGTACCCCT  
 23701 CGAGCTCGAA TGCATGCGAC GCTTTTTCAG CGACCCCGAG ACCTGCGCAA GGTCGAGGAG  
 23761 ACCTGCACTA CACTTTTAGC ACGTTTCGTC AGGCAGGCAT GCAAGATCTC CAACGTGGAG  
 23821 CTGACCAACT GGTCTCTGTC CTGGGAATCC TGCACGAGAA CCGCCTGGGG CAGACAGTGC  
 23881 TCCACTCGAC CCTGAAGGGC GAGGCGCGGC GGGACTATGT CCGCGACTGC GTCTTTCTCT

23941 TTCTCTGCCA CACATGGCAA GCTGCCATGG GCGTGTGGCA GCAGTGTCTC GAGGACGAGA  
24001 ACCTGAAGGA GCTGGACAAG CTTCTTGCTA GAAACCTCAA AAAGCTGTGG ACGGGCTTTG  
24061 ACGAGCGCAC CGTCGCCTCG GACCTGGCCG AGATCGTCCT CCCCCGAGCG CCTGAGGCAG  
24121 ACGCTGAAAG GCGGGCTGCC CGACTTCATG AGCCAGAGCA TGTTCGAAAA CTACCGCACT  
24181 TTCATTCTCG AGCGATCTGG GATGCTGCCC GCCACCTGCA ACGCCTTCCC CTCCGACTTT  
24241 GTCCCGCTGA GCTACCGCGA GTGTCCCCCG CCGCTGTGGA GCCACTGCTA CCTCTTGCAG  
24301 CTGGCCAAC ACATCGCCTA CCCTCGGAT GTTATCGAGG ACGTGAGCGG CGAGGGGCTG  
24361 CTAGAGTGCC ACTGCCGCTG CAACCTGTGC TCTCCGCACC GCTCCTGGTC TGCAACCCCC  
24421 AGCTCCTGAG CGAGACCCAG GTCATCGGTA CCTTCGAGCT GCAAGGTCCG CAGGAGTCCA  
24481 CCGCTCCGCT GAAACTCACG CCGGGGTGTG GGAATTCCGC GTACCTGCGC AAATTTGTAC  
24541 CCGAGGACTA CCACGCCCAT GAGATAAAGT TCTTCGAGGA CCAATCGCGC CCGCAGCAGC  
24601 CGGATCTCAC GGCTTGCCTC ATCACCAGG GCGCGATCCT CGCCCAATTG CACGCCATCC  
24661 AAAAATCCCG CCAAGAGTTT CTTTTGAAAA AGGGTAGAGG GGTCTATCTG GACCCCCAGA  
24721 CGGGCGAAGT GCTCAACCCG GGTCTCCCC AGCATGCCGA AGAAGAACAG AGACCCGCTAG  
24781 TGGAAAGAT GGAAGAAGAA TGGGACAGCC AGCAGAAGAA GACGAATGGG AAGAAGAGAC  
24841 AGAAGAAGAA GAATTGGAAG AGTGGAAGAA GAGCAGCACA GACACCTGCG CCGCACCATC  
24901 CGCGCCGCG CCGGGCGGTC ACGGATACAA CTCGCAGTCC GCCAAGCTCC TCGTAGATGG  
24961 ATCGAGTGAA GGTGACGGTA AGCAGGAGCG GCAGGGCTAC GAATCATGGA GGCCACAAAA  
25021 GCGGGATCAT CGCCTGCTTG CAAGACTGCG GGGGGAACAT CGTTTCGCCC GCCGCTATCT  
25081 GCTCTTCCAT CGCGGGGTGA ACATCCCCCG CAACGTGTTG CATTACTACC GTCACCTTCA  
25141 CAGCTAAGAA AAAATCAGAG TAAGAGGAGT CGCCGGAGGA GGCNTGAGGA TCGCGCGCAA  
25201 CGAGCCATTG ACCACCAGG AGCTGAGGAA TCGGATCTTC CCCACTCTTT ATGCCATTTT  
25261 TCAGCAGAGT CGAGGTCAGC AGCAAGAGT CAAAGTAAAA AACCGGTCTC TGCGCTCGCT  
25321 CACCCGCACT TGCTTGTAAC ACAAAAACGA AGATCAGCTG CAGCGCACTC TCGAAGACGC  
25381 CGAGGCTCTG TTCCACAAGT ACTGCGCGCT CACTCTTAAA GACTAAGGCG CGCCACCCCG  
25441 GAAAAAAGGC GGGAATTACC TCATCGCCAC CATGAGCAAG GAGATTCCCA CCCCTTACAT  
25501 GTGAGCTAT CAGCCCCAGA TGGGCTTGGC CGCGGGCGCC TCCCAGGACT ACTCCACCCG  
25561 CATGAACTGG CTCAGTGCCG GCCCCTCGAT GATCTCACGG GTCAACGGGG TCCGTAACCA  
25621 TCGAAACCAG ATATTGTTGG AGCAGGCGGC GGTCACTCA ACGCCAGGC AAAGCTCAAC  
25681 CCGCGTAATT GGCCCTCCAC CCTGGTGAT CAGGAAATCC CCGGGCCGAC TCCGTTACTA  
25741 CTTCCGCGTG ACGCACTGGC CGAAGTCCGC ATGACTAACT CAGGTGTCCA GCTGGCCGCG  
25801 GCGGCTTCCC GGTGCCCGCT CCGCCACAA TCGGGTATAA AAACCCTGGT GATACGAGGC  
25861 AGAGGCACAC AGCTCAACGA CGAGTTGGTG AGCTCTTCAA TCGGTCTGCG ACCGGACGGA  
25921 GTGTTCCAAC TAGCCGGAGC CGGGAGATCG TCCTTCACTC CCAACCAGGC TACCTGACCT  
25981 TGCAGAGCAG CTCTTCGGAG CCTCGCTCCG GAGGCATCGG AACCTTCCAG TTTGTGGAGG  
26041 AGTTTGTGCC CTCGGTCTAC TTCAACCCCT TCTCGGGATC GCCAGGCCTC TACCCGGACG  
26101 ATGCTTCAAC GAACTTCGAC CGAGTGAGAG AAGCGGTGGA CGGCCACGAC TGAATGTCTT  
26161 ATGGTGACTC GGCTGAGCTC GCTCGGTTGA GGCACCTAGA CCACTGCCGC GCCTCGCGCT  
26221 GCTTCGCCCC GGAGAGCTGC GGACTTATCT ACTTTGAGTT TCCCAGGAG CACCCCAACG  
26281 GCCCTGCACA CGGAGTGCGG ATCACCCTAG AGGGCACCAC CGAGTCTCAC CTGGTTAGGT  
26341 TCTTCAACCA GCAACCTTC CTGGTTCGAG GGGACCGGG AGGCACCACC TACCCGTCT  
26401 ACTGCATCTG TCCAACCCCG AAGTTGCATG AGAATTTTGT TTGTACTCTG TGTGCTGAGT  
26461 TTAATAAAAG CTAAACTCCT ACAATACTCT GGGATCCCGT GTCGTGCGAC TCGCAACAAG  
26521 ACCTTCAACC TCACCAACCA GACTGAGTA AAATTCAACT GCAGACCGGG GGACAAATAC  
26581 ATCCTCTGGC TTTTAAAAA CACTTCCCTC GCAGTCTCCA ACGCCTGCGC CAACGACGGT  
26641 ATTGAAATAC CCAACAACCT TACCAGTGA CTAACCTATA CTACCAGAAA GACTAAGCTA  
26701 GACTCTTACA ATCCTTTTGT AGAGGGAACC TACCACTGCC AGAGCGGACC TTGCTTCCAC  
26761 ACTTTCACCT TGGTGAACGT TACCGACAGC AGCACAGCCG CTACAGAAAC ATCTAACCTT  
26821 CTTTTTGATA CTAACACTCC TAAAACCGGA GGTGAGCTCT GGGTTCCCTC TCTAACAGAG  
26881 GGGGGTAAAC ATATTGAAGC GGTGCGGTAT TTGATTTTAG GGGTGGTCCCT GGGTGGGTGC  
26941 ATAGCGGTGC TGTATTACCT TCCTTGTGG ATCGAAATCA AAATCTTTAT CTGCTGGGTG  
27001 AGACATGTTT GGGAGGAACC ATGAAGGGGC TCTTGCTGAT TATCCTTTCC CTGCTGGGGG  
27061 GTGTACTGTC ATGCCACGAA CAGCCACGAT GTAACATCAC CACAGGCAAT GAGAGGAGTG  
27121 TGATATGCAC AGTAGTCATC AAATGCGAGC ATACATGCCC TCTCAACATC ACATTCAAAA  
27181 ACCGTACCAT GGGAAATGCA TGGGTGGGCG ACTGGGAACC AGGAGATGAG CAGAACTACA  
27241 CGGTCACTGT CCATGGTAGC AATGGAATC ACACCTTTGG TTTCAAATTC ATTTTGAAG  
27301 TCATGTGTGA TATCACACTG CATGTGGCTA GACTTCATGG CTGTGGCCCC CCTACCAAGG

27361 ATAACATGGT TGGGTTTTCT TTGGCTTTTG TGATCATGGC CTGTGCAATG TCAGGTCTGC  
27421 TGGTAGGGGC TTTAGTGTGG TTCCTAAAGC GCAAGCCTAG GTATGGAAAT GAGGAGAAGG  
27481 AAAAATTGCT ATAAATCTTT TCTCTTCGCA GAACCATGAA TACAGTGATC CGTATCGTGC  
27541 TGCTCTCTCT TCTTGTAAC TTTAGTCAGG CAGGATTCAT ACCATCAATG CTACATGGTG  
27601 GGCTAATATA ACTTTAGTGG GACCTCAGAT ATTCCAGATC ACATGGTATG ATAGCACTGG  
27661 ATTGCAATTT TGTGATGGAA GTACAGTTAA GAATCCACAG ATCAGACATA GTTGTAAATGA  
27721 TCAAACTTA ACTCTGATTC ATGTGAACAA AACCCATGAA AGAACATACA TGGGCTATAA  
27781 TAAGCAGAGT ACTCATAAAG AAGACTATAA AGTCACAGTT ATACCACCTC CTCTGTAC  
27841 TGTAAAGCCA CAACCAGAGC CAGAATATGT GTATGTTAAT ATGGGAGAGA ACAAACCTT  
27901 AGTTGGGCCT CCAGGAATTC CAGTTAGTTG GTTTAATCAG GATGGTTTAC AATTTTGCAT  
27961 TGGGGATAAA GTTTTTCATC CAGAATTCAA CCACACCTGT GACATGCAAA ATCTTACACT  
28021 GTTGTTTATA AATCTTACAC ATGATGGAGC TTATCTTGGT TATAATCGCC AGGGAACCTGA  
28081 AAGAACCTGG TATGAGGTGG TAGTGTCAGA TGGTTTCCA AAATCAGAA AGATGAAGGT  
28141 AGAAGACCAT AGTAAAGAAA CAGAACAAA ACAGACTGGT CAAAAACAAA GTGACCATAA  
28201 GCAGGGTGGG CAAAAAGAAA CAAGTCAAAA GAAAACTAAT GACAAACAAA AGCCATCGCG  
28261 CAGGAGGCCA TCTAACTAA AGCCAAACAC ACCTGACACA AAATAATTA CAGTCACTAG  
28321 TGGGTCAAAC GTAACCTTAG TTGGTCCAGA TGGAAAGGTC ACTGGGTATG ATGATGATTT  
28381 AAAAGACCA TGTGAGCCTG GGTATAAGTT AGGGTGTAAG TGTGACAATC AAAACCTAAC  
28441 CCTAATCAAT GTAACATAAC TTTATGAGGG AGTTTACTAT GGTACTAATG ACAGAGGCAA  
28501 CAGCAAAAGA TACAGAGTAA AAGTAAACAC TACTAATTCT CAAAGTGTA AAATTCAGCC  
28561 GTACACCAGG CCTACTACTC CTGATCAGAA ACACAGATTT GAATTGCAAA TTGATTCTAA  
28621 TCAAGACAAA ATTCCATCAA CTACTGTGGC AATCGTGGTG GGAGTGATCG CGGGCTTTGT  
28681 AACTCTAATC ATTATTTTCA TATGCTACAT CTGCTGCCGC AAGCGTCCCA GGTCATACAA  
28741 TCATATGGTA GACCCACTAC TCAGCTTCTC TTAGTGAAAC TCAGTCACTC TCATTTTACA  
28801 ACCATGAAGG CTTTCACAGC TTGCGTTCTG ATTAGCATAG TCACACTTAG TTCAGCTGCA  
28861 ATGATTAAATG TTAATGTCAC TAGAGGTGGT AAAATTACAT TGAATGGGAG TTATCCACAA  
28921 ACTACATGGA CAAGATATCA TAAAGATGGA TGGAAAAATA TTTGTGAATG GAATGTTACT  
28981 GCATACAAAT GCTTCAATAA TGGAAGCATT ACTATTACTG CCACTGCCAA CATTGTTCTT  
29041 GGCACATACA AAGCTGAAAG CTATAAAAAAT GAAATTAAAA AATTAACCTA TAAAAACAAC  
29101 AAAACCACAT TTGAAGATTC TGGAAATTAT GAGCATCAAA AATTATCTTT TTATATGTTG  
29161 ACAATAATTG AACTGCCTAC AACCAAGGCA CCCACCACAG TTAGTACAAC TACACAGTCA  
29221 ACTGTAAAGA CCACTACTCA CACTACACAG CTAGACACCA CAGTGCAGAA TAATACTGTG  
29281 TTGGTTAGGT ATTTGTTGAG GGAGGAAAGT ACTACTGAAC AGACAGAGGC TACCTCAAGT  
29341 GCCTTTATCA GCCTGCAAA TTTAACTTTC CTGCTTGGG CTAATGAAAC CGGAGTATCA  
29401 TTAAGGCTCA GCCAGCCTTA CTCAGCTTGG GATATTCAA TTTACTTTCT GTTGTCTGT  
29461 GGGATCTTTA TTCTTGTGGT TCTTCTGTAC TTTGTCTGCT GTAAAGCCAG AAAGAAATCT  
29521 AGGAGGCCCA TCTACAGGCC AGTGATTGGG GAACCTCAGC CACTCCAAGT GGATGGAGGC  
29581 TTAAGGAATC TTCTTTTCTC TTTTACAGTA TGGTGATCAG CCATGATTCC TAGTTCTTCC  
29641 TATTTAACAT CCTCTTCTGT CTCTTCAACA TCTGTGCTGC CTTTGCAGCA GTTTCGCACG  
29701 CCTCGCCCCG CTGTCTAGGG CCTTTCCCCA CCTACTCCTC TTTGCCCTGC TCACCTGCAC  
29761 CTGCGTCTGC AGCATTGTCT GCCTGGTCAT CACCTTCCTG CAGCTCATCG ACTGGTGCTG  
29821 CGCGCGCTAC AATTACTTCA TCATAGTCCC GAATACAGGG ACGAGAACGT AGCCAGAATT  
29881 TTAAGGCTCA TATGACCATG CAGACTCTGC TCATACTGCT ATCGCTCTTA TCCCATGCC  
29941 TCGCTACTGC TGATTACTCT AAATGCAAA TGGCGGACAT ATGGAATTTT TTAGACTGCT  
30001 ATCAGGAGAA AATTGATATG CCCTCCTATT ACTTGGTGAT TGTGGGAATA GTTATGGTCT  
30061 GCTCCTGCAC TTTCTTTGCC ATCATGATCT ACCCCTGTTT TGATCTTGGA TGGAACTCTG  
30121 TTGAGGCATT CACATACACA CTAGAAAGCA GTTCACTAGC CTCCACGCCA CCACCCACAC  
30181 CGCCTCCCCG CAGAAATCAG TTTCCCATGA TTCAGTACTT AGAAGAGCCC CCTCCCCGAC  
30241 CCCCTTCCAC TGTAGCTAC TTTACATAA CCGGCGGCGA TGAATGACCA CCACCTGGAC  
30301 CTCGAGATGG ACGGCCAGGC CTCCGAGCAG CGCATCCTGC AACTGCGCGT CCGTCAGCAG  
30361 CAGGAGCGTG CCGCCAAGGA GCTCCTCGAT GCCATCAACA TCCACCAGTG CAAGAAGGGC  
30421 ATCTTCTGCC TGGTCAAACA GGCAAAGATC ACCTACGAGC TCGTGTCCAA CGGCAAACAG  
30481 CATCGCCTCA CCTATGAGAT GCCCCAGCAG AAGCAGAAGT TCACCTGCAT GGTGGGCGTC  
30541 AACCCCATAG TCATACCCA GCAGTCGGGC GAGACCAACG GCTGCATCCA CTGCTCCTGC  
30601 GAAAGCCCCG AGTGATCTA CTCCCTTCTC AAGACCTTT GCGGACTCCG CGACCTCCTC  
30661 CCCATGAACT GATGTTGATT AAAAACAAA AAAACAATC AGCCCTTCC CCTATCCCAA  
30721 ATTACTCGCA AAAATAAATC ATTGGAAC TAATTTAAT AAAGATCACT TACTTGAAT

30781 CTGAAAGTAT GTCTCTGGTG TAGTTGTTCA GCAGCACCTC GGTACCCTCC TCCCAACTCT  
30841 GGTACTCCAG TCTCCGGCGG GCGGCGAACT TTCTCCACAC CTTGAAAGGG ATGTCAAATT  
30901 CCTGGTCCAC AATTTTCATT GTCTTCCCTC TCAGATGTCA AAGAGGCTCC GGGTGGAAAG  
30961 TGACTTCAAC CCCGTCTACC CCTATGGCTA CGCGCGGAAT CAGAATATCC CCTTCTCAC  
31021 TCCCCCTTT GTCTCTCCG ATGGATTCAA AAACCTCCCC CCTGGGGTCC TGCTACTCAA  
31081 ACTGGCTGAC CCAATCACCA TAGCCAATGG TGATGTCTCA CTCAAGGTGG GAGGGGACTT  
31141 ACTTTGCAAG AAGGAAGTAT GACTGTAGAC CCTAAGGCTC CCTTGCAACT TGCAAACAAT  
31201 AAAAAAATTG AGCTTGTTTA TGTTGATCCA TTTGAGGTTA GTGCCAATAA ACTTAGTTTA  
31261 AAAGTAGGAC ATGGATTAAA AATATTAGAT GACAAAAGTG CTGGAGGGTT GAAAGATTTA  
31321 ATTGGCAAAC TTGTGGTTTT AACAGGGGAA AGGAATAGGC ACTGAAAATT TGCAAAATAC  
31381 AGATGGTAGC AGCAGAGGAA TTGGTATAAG TGTAAGAGCA AGAGAAGGGT TAACATTTGA  
31441 CAATGATGGA TACTTGGTAG CATGGAACCC AAAGTATGAC ACGCGCACAC TTTGGACAAC  
31501 ACCAGACACA TCTCCTAATT GCAGGATTGA TAAGGAGAAG ATTCAAACT CACTTTGGTA  
31561 CTTACAAAGT GTGGAAGTCA AATATTAGCT AATGTGTCTT TGATTGTGGT GTCAGGAAAA  
31621 TTTGATAATA TAGACCACGC TACAAATCCA ACTCTTAAAT CATTAAAAAT AAAACTTCTT  
31681 TTTGATAATA AAGGTGTA CTCTCCCACT TCAAACTTG ATTCCACATA TTGGAATTTT  
31741 AGAAGTGACA ATTTAACTGT ATCTGAGGCA TATAAAAAATG CAGTTGAATT TATGCCTAAT  
31801 TTGGTAGCCT ACCCAAAACC TACCACTGGC TCTAAAAAT ATGCAAGGGA TATAGTCTAT  
31861 GGGAACATAT ATCTTGGAGG TTTGGCATAT CAGCCAGTTG TAATTAAGGT TACTTTTAAT  
31921 GAAGAAGCAG ATAGTGCTTA CTCTATAACA TTTGAATTTG TATGGAATAA AGAATATGCC  
31981 AGGGTTGAAT TTGAAACCAC TTCTTTTACC TTCTCCTATA TTGCCCAACA ATAAAAGACC  
32041 AATAAACGTG TTTTTTATTT CAAATTTTAT GTATCTTTAT TGATTTTAC ACCAGCGCGA  
32101 GTAGTCAATC TCCCACCACC AGCCCATTTT ACAGTGATACA CGGTCTCTC AGCACGGTGG  
32161 CCTTAAATAA GGAAATGTTT TGATTATTGC GGGAACTGGA CTGGGGTCT ATAATCCACA  
32221 CAGTTTCTCTG ACGAGCCAAA CGGGGATCGG TGATTGAAAT GAAGCCGTCC TCTGAAAAGT  
32281 CATCCAAGCG GGCCTCACAG TCCAGGTCAC AGTCTGGTGG AACGAGAAGA ACGCACAGAT  
32341 TCATACTCGG AAAACAGGAT GGGTCTGTGC CTCTCCATCA GCGCCCTCAG CAGTCTCTGC  
32401 CGCCGGGGCT CGGTGCGGCT GCTGCAAAATG GGATCGGGAT CACAAGTCTC TCTAACTATG  
32461 ATCCCAACAG CCTTCAGCAT CAGTCTCTCTG GTGCGTCCAG CACAGCACCG CATCTGATC  
32521 TCTGCCATGT TCTCACAGTA AGTCAGCAC ATAATCACCA TGTATTTCAG CAGCCATAA  
32581 TTCAGGGTGC TCCAGCCAAA GCTCATGTTG GGGATGATGG AACCACAGTG ACCATCGTAC  
32641 CAGATGCGGC AGTATATCAG GTGCCTGCCC CTCATGAACA CACTGCCCAT ATACATGATC  
32701 TCTTTGGGCA TGTTTCTGTT TACAATCTGG CGGTACCAGG GGAAGCGCTG GTTGAACATG  
32761 CACCCGTAAA TGACTCTCCT GAACCACACG GCCAGCAGGG TGCCCTCCCGC CCGACACTGC  
32821 AGGGAGCCAG GGGATGAACA GTGGCAATGC AGGATCCAGC GCTCGTACCC GCTCACCATC  
32881 TGAGCTCTTA CCAAGTCCAG GGTAGCGGG CACAGGCACA CTGACATACA TCTTTTAAA  
32941 ATTTTATTTT CCTCTGTGGT GAGGATCATA TCCCAGGGGA CTGGAACTC TTGGAGCAGG  
33001 GTAAAGCCAG CAGCACATGG TAATCCACGG ACAGAACTTA CATTATGATA ATCTGCATGA  
33061 TCACAATCGG GCAACAGGGG ATGTTGATCA GTCAGTGAAG CCCTGGTTTC ATCATCAGAT  
33121 CGTGGTAAAC GGGCCCTGCG ATATGGATGA TGGCGGAGCG AGCTGGATTG AATCTCGGTT  
33181 TGCATTGTAG TGGATTCTCT TCGGTACCTT GTCGTACTTC TGCCAGCAGA AATGGGCCCT  
33241 TGAACAGCAT ATACCCCTCC TGCGGCCGTC CTTTCGCTGC TGCCGCTCAG TCATCCAACT  
33301 GAAGTACATC CATCTCTGAA GATTCTGGAG AAGTTCCTCT GCATCTGATG AAATAAAAAA  
33361 CCCGTCCATG CGAATTCCCC TCATCACATC AGCCAGGACT CTGTAGGCCA TCCCCATCCA  
33421 GTTAATGCTG CTTGTCTAT CATTACAGAG GGGCGGTGGC AGGATTGGAA GAACCATTTT  
33481 TATTCCAAAC GGTCTCGAAG GACGATAAAG TGCAAGTCAC GCAGGTGACA GCGTTCCTCT  
33541 CCGCTGTGCT GGTGGAAACA GACAGCCAGG TCAAAACCCA CTCTATTTTC AAGGTGCTCG  
33601 ACCGTGGCTT CGAGCAGTGG CTCTACGCGT ACATCCAGCA TAAGAATCAC ATTAAAGGCT  
33661 GGCCCTCCAT CGATTTCATC AATCATCAGG TTACATTCCT GCACCATCCC CAGGTAATTC  
33721 TCATTTTTC AGCCTTGGAT TATCTCTACA AATGTGTGGT GTAAATCCAC TCCGCACATG  
33781 TTGAAAAGCT CCCACAGTGC CCCCTCCACT TTCATAATCA GGCAGACCTT CATAATAGAA  
33841 ACAGATCTCT GTGCTCCACC ACCTGCAGCG TGTTCAAAAC AACAAGATT CATAAGGTTT  
33901 TGCCCTCCGC CCTGAGCTCG CGCCTCAATG TCAGCTGCAA AAAGTCACTT AAGTCTGGG  
33961 CCACTACAGC TGACAATTCA GAGCCAGGGC TAAGCGTGGG ACTGGCAAGC GTGAGGGAAA  
34021 ACTTTAATGC TCCAAAGCTA GCACCCAAA ACTGCATGCT GGAATAAGCT CTCTTGTGT  
34081 CTCCGGTGAT GCCTTCCAAA ATGTGAGTGA TAAAGCGTGG TAGTTTTTTC TTTAATCATT  
34141 TGCGTAATAG AAAAGTCCTG TAAATAAGTC ACTAGGACCC CAGGGACCAC AATGTGGTAG

- 38 -

|       |            |            |             |            |            |            |
|-------|------------|------------|-------------|------------|------------|------------|
| 34201 | CTTACACCGC | GTCGCTGAAA | GCATGGTTAG  | TAGAGATGAG | AGTCTGAAAA | ACAGAAAGCA |
| 34261 | TGCGCTAAAC | TAAGGTGGCT | ATTTTCACTG  | AAGGAAAAAT | CACTCTTTCC | AGCAGCAGGG |
| 34321 | TACCCACTGG | GTGGCCCTTG | CGGACATACA  | AAAATCGGTC | CGTGTGATTA | AAAAGCAGCA |
| 34381 | CAGTAAGTTC | CTGTCTTCTT | CCGGCAAAAA  | TCACATCGGA | CTGGGTTAGT | ATGTCCCTGG |
| 34441 | CATGGTAGTC | ATTCAAGGCC | ATAAATCTGC  | CCTGATATCC | AGTAGGAACC | AGCACACTCA |
| 34501 | CTTTTAGGTG | AAGCAATACC | ACCCCATGCG  | GAGGAATGTG | GAAAGATTCA | GGGCAAAAAA |
| 34561 | AATTATATCT | ATTGCTAGCC | CTTCCTGGAC  | GGGAGCAATC | CTCCAGGACT | ATCTATGAAA |
| 34621 | GCATACAGAG | ATTCAGCCAT | AGCTCAGCCC  | GCTTACCAGT | AGACAAAGAG | CACAGCAGTA |
| 34681 | CAAGCGCCAA | CAGCAGCGAC | TGACTACCCA  | CTGACTTAGC | TCCCTATTTA | AAGGCACCTT |
| 34741 | ACACTGACGT | AATGACCAAA | GGTCTAAAAA  | CCCCGCCAAA | AAAACACACA | CGCCCTGGGT |
| 34801 | GTTTTTGCGA | AAACACTTCC | GC GTTCTCAC | TTCTTCGTAT | CGATTTCTGT | ACTTGACTTC |
| 34861 | CGGGTTCCCA | CGTTACGTCA | CTTTTGCCCT  | TACATGTAAC | TTAGTCGTAG | GGCGCCATCT |
| 34921 | TGCCCACGTC | CAAAATGGCT | TACATGTCCA  | GTTACGCCTC | CGCGCGGACC | GTTAGCCGTG |
| 34981 | CGTCGTGACG | TCATTTGCAT | CAACGTTTCT  | CGGCCAATCA | GCAGTAGCCC | CGCCCTAAAT |
| 35041 | TTAAAACCTC | ATTTGCATAT | TAACTTTTGT  | TTACTTTGTG | GGGTATATTA | TTGATGATG  |



ATGTCAAAGAGGCTCCGGGTGGAAGATGACTTCAACCCCGTCTACCCCTA  
TGGCTACGCGCGGAATCAGAATATCCCCTTCCTCACTCCCCCCTTTGTCTC  
CTCCGATGGATTCAAAAACCTCCCCCCTGGGGTCCTGTCACTCAAACCTGGC  
TGACCCAATCACCATAGCCAATGGTGATGTCTCACTCAAGGTGGGAGGGG  
GACTTACTTTGCAAGAAGGAAGTCTGACTGTAGACCCTAAGGCTCCCTTG  
CAACTTGCAAACAATAAAAAACTTGAGCTTGTTTATGTTGATCCATTTGAG  
GTTAGTGCCAATAAACTTAGTTTAAAAGTAGGACATGGATTAAAAATATT  
AGATGACAAAAGTGCTGGAGGGTTGAAAGATTTAATTGGCAAACCTTGTTG  
TTTTAACAGGGAAAGGAATAGGCACTGAAAATTTGCAAATAACAGATGGT  
AGCAGCAGAGGAATTGGTATAAGTGTAAGAGCAAGAGAAGGGTTAACAT  
TTGACAATGATGGATACTTGGTAGCATGGAACCCAAAGTATGACACGCGC  
ACACTTTGGACAACACCAGACACATCTCCTAATTGCAGGATTGATAAGGA  
GAAGGATTCAAACTCACTTTGGTACTTACAAAGTGTGGAAGTCAAATAT  
TAGCTAATGTGTCTTTGATTGTGGTGTCAGGAAAATATCAATACATAGACC  
ACGCTACAAATCCAACCTCTTAAATCATTTAAAATAAACTTCTTTTTGATA  
ATAAAGGTGTACTTCTCCCAAGTTCAAACCTTGATTCCACATATTGGAAC  
TTAGAAGTGACAATTTAACTGTATCTGAGGCATATAAAAATGCAGTTGAA  
TTTATGCCTAATTTGGTAGCCTACCCAAAACCTACCACTGGCTCTAAAAAA  
TATGCAAGGGATATAGTCTATGGGAACATATATCTTGGAGGTTTGGCATA  
TCAGCCAGTTGTAATTAAGGTTACTTTTAATGAAGAAGCAGATAGTGCTTA  
CTCTATAACATTTGAATTTGTATGGAATAAAGAATATGCCAGGGGTTGAA  
TTTGAAACCACTTCCTTTACCTTCTCCTATATTGCCCAACAATAA

SEQ ID NO:2

**SUBSTITUTE SHEET (RULE 26)**

Penton17.Seq Length: 1554

```
1  ATGAGGCGTG CCGTGGTGTC TTCCTCTCCT CCTCCCTCGT ACGAGAGCGT
51  GATGGCGCAG GCGACCCTGG AGGTTCCGTT TGTGCCTCCG CCGTATATGG
101 CTCCTACGGA GGGCAGAAAC AGCATTCTGT ACTCGGAGCT GGCTCCGTTG
151 TACGACACCA CTCGCGTGTA CTTGGTGGAC AACAAAGTCGG CGGACATCGC
201 TTCCCTGAAC TATCAAAACG ACCACAGCAA CTTCCCTGACC ACGGTGGTGC
251 AGAACAAACG TTTCACCCCC GCCGAGGCTA GCACGCAGAC GATAAATTTT
301 GACGAGCGGT CGCGGTGGGG CGGTGATCTG AAGACCATTG TGCACACCAA
351 CATGCCCAAT GTGAACGAGT ACATGTTTAC CAGCAAGTTT AAGGCGCGGG
401 TGATGGTGGC TAGAAAACAC CCACAGGGGG TAGAAGCAAC AGATTTAAGC
451 AAGGATATCT TAGAGTATGA GTGGTTTGAG TTTACCCTGC CCGAGGGCAA
501 CTTTTCCGAG ACCATGACCA TAGACCTGAT GAACAACGCC ATCTTGAAAA
551 ACTACTTGCA AGTGGGGCGG CAAAATGGCG TGCTGGAGAG CGATATTGGA
601 GTCAAGTTTG ACAGCAGAAA TTTCAAGCTG GGCTGGGACC CTGTGACCAA
651 GCTGGTGATG CCAGGGGTCT ACACCTACGA GGCCTTTCAC CCGACGTTGG
701 TGCTGCTGCC GGGCTGCGGG GTGGACTTCA CAGAGAGCCG CCTGAGCAAC
751 CTCCTGGGCA TTCGCAAGAA GCAACCTTTC CAAGAGGGCT TCAGAATCAT
801 GTATGAGGAT CTAGAAGGGG GCAACATCCC CGCCCTGCTG GATGTGCCCCA
851 AGTACTTGGA AAGCAAGAAG AAGTTAGAGG AGGCATTGGA GAATGCTGCT
901 AAAGCTAATG GTCCTGCAAG AGGAGACAGT AGCGTCTCAA GAGAGGTTGA
951 AAAGGCAGCT GAAAAAGAAC TTGTTATTGA GCCCATCAAG CAAGATGATA
1001 CCAAGAGAAG TTACAACCTC ATCGAGGGAA CCATGGACAC GCTGTACCGC
1051 AGCTGGTACC TGTCTATAC CTACCGGGAC CCTGAGAACG GGGTGCAGTC
1101 GTGGACGCTG CTCACCACCC CGGACGTCAC CTGCGGCGCG GAGCAAGTCT
1151 ACTGGTCGCT GCCGGACCTC ATGCAAGACC CCGTCACCTT CCGTTCTACC
1201 CAGCAAGTCA GCAACTACCC CGTGGTCGGC GCCGAGCTCA TGCCCTTCCG
1251 CGCCAAGAGC TTTTACAACG ACCTCGCCGT CTAATCCCAG CTCATCCGCA
1301 GCTACACCTC CCTCACCCAC GTCTTCAACC GCTTCCCCGA CAACCAGATC
```

SEQ ID NO: 3

1351 CTCTGCCGTC CGCCCGCGCC CACCATCACC ACCGTCAGTG AAAACGTGCC  
1401 TGCTCTCACA GATCACGGGA CGCTACCGCT GCGCAGCAGT ATCCGCGGAG  
1451 TCCAGCGAGT GACCGTCACT GACGCCCCGTC GCCGCACCTG TCCCTACGTC  
1501 TACAAGGCCC TGGGCATAGT CGCGCCGCGT GTGCTTTCCA GTCGCACCTT  
1551 CTAA

- 42 -

Claims

1. A chimeric adenoviral vector comprising nucleotide sequence of a first  
adenovirus, wherein at least one gene of said first adenovirus encoding a  
5 protein that facilitates binding of said vector to a target mammalian cell, or  
internalization thereof within said cell, is replaced by the corresponding gene  
from a second adenovirus belonging to subgroup D, said vector further  
comprising a transgene operably linked to a eucaryotic promoter to allow for  
expression therefrom in a mammalian cell.  
10
2. A chimeric adenoviral vector according to Claim 1 wherein said second  
adenovirus is selected from the group consisting of Ad 9, Ad 15, Ad 17, Ad  
19, Ad 20, Ad 22, Ad 26, Ad 27, Ad 28, Ad 30, and Ad 39.
- 15 3. A chimeric adenoviral vector according to Claim 1 wherein said first  
adenovirus is selected from the group consisting of Ad 2, Ad 5, and Ad 12.
4. A chimeric adenoviral vector according to Claim 1 wherein said replaced gene  
encodes Ad fiber.  
20
5. A chimeric adenoviral vector according to Claim 1 wherein said replaced gene  
encodes Ad penton base.
6. A chimeric adenoviral vector according to Claim 1 wherein a first replaced  
25 gene encodes Ad fiber, and a second replaced gene encodes Ad penton base.
7. A chimeric adenoviral vector comprising nucleotide sequence of a first  
adenovirus, wherein a portion of a gene thereof encoding a protein that  
facilitates binding of said vector to a target mammalian cell, or internalization

- 43 -

thereof within said cell, is replaced by a portion of the corresponding gene from a second adenovirus belonging to subgroup D, said vector further comprising a transgene operably linked to a eucaryotic promoter to allow for expression therefrom in a mammalian cell.

5

8. A chimeric adenoviral vector according to Claim 7 wherein the encoding sequence that is replaced codes for a portion of Ad fiber.

9. A chimeric adenoviral vector according to Claim 7 wherein the encoding sequence that is replaced codes for a portion of Ad penton base.

10

10. A chimeric adenoviral vector according to Claim 9 wherein the encoding sequence that is replaced codes for an amino acid sequence that includes RGD.

11. A method of providing a biologically active protein to the airway epithelial cells of a patient comprising administering to said cells an adenoviral vector selected from the group consisting of:

15

20

25

(a) a chimeric adenoviral vector comprising nucleotide sequence of a first adenovirus, wherein at least one gene of said first adenovirus encodes a protein that facilitates binding of said vector to a target mammalian cell, or internalization thereof within said cell, is replaced by the corresponding gene from a second adenovirus belonging to subgroup D, said vector further comprising a transgene encoding said protein that is operably linked to a eucaryotic promoter to allow for expression therefrom in a mammalian cell; and

(b) a chimeric adenoviral vector comprising nucleotide sequence of a first adenovirus, wherein a portion of a gene thereof encoding a protein that facilitates binding of said vector to a target mammalian cell, or internalization thereof within said cell, is replaced by a portion of the

- 44 -

corresponding gene from a second adenovirus belonging to subgroup D, said vector further comprising a transgene encoding said protein that is operably linked to a eucaryotic promoter to allow for expression therefrom in a mammalian cell;

5 under conditions whereby the transgene encoding said protein is expressed, and phenotypic benefit is produced in said airway epithelial cells.

12. A method according to Claim 11 wherein said second adenovirus is Ad 17 and the nucleotide sequence thereof used in replacement of nucleotide sequence of  
10 said first adenovirus encodes a polypeptide selected from the group consisting of Ad 17 fiber, a fragment of Ad 17 fiber, Ad 17 hexon, a fragment of Ad 17 hexon, Ad penton base, and a fragment of Ad 17 penton base.

13. A method of providing a biologically active protein to the airway epithelial  
15 cells of a patient that comprises administering to said cells an adenoviral vector comprising elements of an Ad 17 genome, and a transgene encoding said protein that is operably linked to a eucaryotic promoter to allow for expression therefrom in a mammalian cell, under conditions whereby the transgene encoding said protein is expressed, and phenotypic benefit is  
20 produced in said airway epithelial cells.

1/17





FIG 1 - original FIG 1 in PTO  
is full color - see side Solder

BEST AVAILABLE COPY

2/17



F16 2 - original 5.6od in FTO  
is Full color - see side folder

BEST AVAILABLE COPY



3/17




FIGURE 3

BEST AVAILABLE COPY

4/17


Chimeric Ad2/ $\beta$ gal-2/ Ad17 vectors

FIGURE 4

BEST AVAILABLE COPY

5/17

[illegible]

FIGURE 5A



7/17

//

|           |  |  |     |                 |
|-----------|--|--|-----|-----------------|
|           | 1  |  | 50  |                 |
| Penton5   | ...MRRRAAM. ....YEEGP PPSYESVUSA ..APVAAALG SPFDAPLDPP |  |     | ← SEQ ID NO: 6  |
| Penton2   | ...MQRAAM. ....YEEGP PPSYESVUSA ..APVAAALG SPFDAPLDPP  |  |     | ← SEQ ID NO: 5  |
| Penton3   | ...MRRRAVLG GAV.VYPEGP PPSYESVM.. ....QQQA AMIQPPLEAP  |  |     | ← SEQ ID NO: 7  |
| Penton12  | ...MRRRAVEL QTV.AFPETP PPSYETVM.. ....AAAPP            |  |     | ← SEQ ID NO: 8  |
| Penton40  | ...MRRRAVG VPMAYAEGP PPSYESVM.. ....ET ADLPATLQAL      |  |     | ← SEQ ID NO: 9  |
| Penton17  | ...MRRRAVV. ....SSSP PPSYESVM.. ....A... ..QATLEVP     |  |     | ← SEQ ID NO: 4  |
| Pentonf10 | MWGLQPPTSI PPPPPTELT PSTYPAMVNG YPPPAASAQS CSSSGGQSEL  |  |     | ← SEQ ID NO: 10 |
|           | 51   |  | 100 |                 |
| Penton5   | FVP.PRYLRP TGGRNSIRYS ELAPLFDTR VYLVDNKSTD VASLNYQNDH  |  |     |                 |
| Penton2   | FVP.PRYLRP TGGRNSIRYS ELAPLFDTR VYLVDNKSTD VASLNYQNDH  |  |     |                 |
| Penton3   | FVP.PRYLAP TEGRNSIRYS DVSPLYDTTK LYLVDNKSD IASLNYQNDH  |  |     |                 |
| Penton12  | YVP.PRYLGP TEGRNSIRYS ELSPLYDTTR VYLVDNKSSD IASLNYQNDH |  |     |                 |
| Penton40  | HVP.PRYLGP TEGRNSIRYS ELAPLYDTTR VYLVDNKSD IASLNYQNDH  |  |     |                 |
| Penton17  | FVP.PRYMAP TEGRNSIRYS ELAPLYDTTR VYLVDNKSD IASLNYQNDH  |  |     |                 |
| Pentonf10 | YMPLQVRMAP TGGRNSIKYR DYTPCRNTTK LFYVDNKASD IDTYNKDANH |  |     |                 |
|           | 101  |  | 150 |                 |
| Penton5   | SNFLTTVIQN NDYSPGEAST QTINLDDRSR WGGDLKTILH TNMPNVNEFM |  |     |                 |
| Penton2   | SNFLTTVIQN NDYSPGEAST QTINLDDRSR WGGDLKTILH TNMPNVNEFM |  |     |                 |
| Penton3   | SNFLTTVVQN NDFTPTFAST QTINFDESR WGGQLKTIMH TNMPNVNEYM  |  |     |                 |
| Penton12  | SNFLTTVVQN NDYSPIEAGT QTINFDESR WGGDLKTILH TNMPNVNDFM  |  |     |                 |
| Penton40  | SNFQTTVVQN NDFTPTFAST QTINFDESR WGGDLKTILR TNMPNINEFM  |  |     |                 |
| Penton17  | SNFLTTVVQN NDFTPAEAST QTINFDESR WGGDLKTILH TNMPNVNEYM  |  |     |                 |
| Pentonf10 | SNFRTTVIHN QDLADTAAT ESIQLDNRSC WGGDLKTAVR TNCNVSSFF   |  |     |                 |
|           | 151  |  | 200 |                 |
| Penton5   | FTNKFKARVM VSRL..... ..PTKD..N QVELKYEWVE FTLPEGNYSE   |  |     |                 |
| Penton2   | FTNKFKARVM VSRS..... ..LTKD..K QVELKYEWVE FTLPEGNYSE   |  |     |                 |
| Penton3   | FSNKFKARVM VSRKAPEGVT VNDTYDH..K EDILKYEWFE FILPEGNFSA |  |     |                 |
| Penton12  | FTTKFKARVM VARK..... ..TNNE..G QTILEYEWAE FVLPEGNYSE   |  |     |                 |
| Penton40  | STNKFRARVM VEK..... ..VNR..K TNAPRYEWFE FTLPEGNYSE     |  |     |                 |
| Penton17  | FTSKFKARVM VARKHPQGV. ..EATDL..S KDILEYEWFE FTLPEGNFSE |  |     |                 |
| Pentonf10 | QSNVSVRVM WKRDPTSTA PPSAVGSGYS VPGAQYKWD LTVPEGNYAL    |  |     |                 |
|           | 201  |  | 250 |                 |
| Penton5   | TMTIDLMNNA IVEHYLKVGR ONGVLESDIG VKFDTRNFRL GFDPVTGLVM |  |     |                 |

FIGURE 6A

8/17

|           |            |             |             |            |            |
|-----------|------------|-------------|-------------|------------|------------|
| Penton2   | TMTIDLMNNA | IVEHYLA.VGR | QNGVLES DIG | VKFDTRNFRL | GFDPVTKLVM |
| Penton3   | TMTIDLMNNA | IIDNYLEIGR  | QNGVLES DIG | VKFDTRNFRL | GWDPEPKLIM |
| Penton12  | TMTIDLMNNA | IEHYLRVGR   | QNGVLES DIG | VKFDTRNFRL | GWDPEPKLVT |
| Penton40  | TMTIDLMNNA | IVDNYLAVGR  | QNGVLES DIG | VKFDTRNFRL | GWDPEPKLVM |
| Penton17  | TMTIDLMNNA | ILENYLQVGR  | QNGVLES DIG | VKFDTRNFRL | GWDPEPKLVM |
| Pentonf10 | CELIDLLNEG | IVQYLSEGR   | QNNVQKSDIG  | VKFDTRNFGL | LRDPVTKLVT |

251

300

|           |            |             |            |            |            |
|-----------|------------|-------------|------------|------------|------------|
| Penton5   | PGVYTNEAFH | PDIILLPGCG  | VDFTSRLSN  | LLGIRKQPF  | QEGFRITYDD |
| Penton2   | PGVYTNEAFH | PDIILLPGCG  | VDFTSRLSN  | LLGIRKQPF  | QEGFRITYDD |
| Penton3   | PGVYTNEAFH | PDIIVLLPGCG | VDFTSRLSN  | LLGIRKRHPF | QEGFKIMYED |
| Penton12  | PGVYTNEAFH | PDIIVLLPGCG | VDFTSRLSN  | LLGIRKRHPF | QEGFKIMYED |
| Penton40  | PGVYTNEAFH | PDIIVLLPGCG | VDFTSRLSN  | LLGIRKRMPF | QEGFKIMYED |
| Penton17  | PGVYTNEAFH | PDIIVLLPGCG | VDFTSRLSN  | LLGIRKRMPF | QEGFKIMYED |
| Pentonf10 | PGTVYKGYH  | PDIIVLLPGCA | IDFTYSRLSL | LLGIRKREPY | SKGFVITYED |

301

350

|           |            |            |            |              |            |
|-----------|------------|------------|------------|--------------|------------|
| Penton5   | LEGGNIPALL | DVDAYQASLK | DDTEQGGGA  | GGSNSSGSGA   | EENSNAASAA |
| Penton2   | LEGGNIPALL | DVDAYQASLK | DDTEQGGGA  | GGSNSSGSGA   | EENSNAASAA |
| Penton3   | LEGGNIPALL | DVTAYEESKK | DTTETTTTLA | VAEETSE...   | .....      |
| Penton12  | LEGGNIPALL | DVKKYENSL  | .....      | Q...         | .....      |
| Penton40  | LEGGNIPALL | DVEKYEASIK | .....      | .....        | .....      |
| Penton17  | LEGGNIPALL | DVPKYLESKK | KLE.....   | E ALENAAK... | .....      |
| Pentonf10 | LQGGDIPALL | DLDSVDVND  | DGEVIELDNA | A.....       | .....      |

351

400

|           |            |                |             |            |            |
|-----------|------------|----------------|-------------|------------|------------|
| Penton5   | MQPVEDMNDH | AIRGDTFATR     | AEEKRAEAEA  | AAEAAAPAAQ | PEVEKPQKKP |
| Penton2   | MQPVEDMNDH | AIRGDTFATR     | AEEKRAEAEA  | AAEAAAPAAQ | PEVEKPQKKP |
| Penton3   | .....      | DD ITRGDTYITE  | KQKREAAAE   | V.....     | .....KKEL  |
| Penton12  | .....      | DQN TVRGDNFIA  | .....       | L.....     | .....NKAA  |
| Penton40  | .....      | EAQ EIRGADFKPN | PQ.....     | .....      | .....DL    |
| Penton17  | .....      | ANG PARGDSSVSR | EVEKAA..... | .....      | .....EKEL  |
| Pentonf10 | .....      | .....          | .....       | .....      | .....      |

401

450

|           |            |            |            |            |             |
|-----------|------------|------------|------------|------------|-------------|
| Penton5   | VIKPLTEDSK | KRSYNLI... | SNDSTFTQYR | SWLAYNYGD  | PQTGIRSWTL  |
| Penton2   | VIKPLTEDSK | KRSYNLI... | SNDSTFTQYR | SWLAYNYGD  | PQTGIRSWTL  |
| Penton3   | KIOPLEKDSK | SRSYNVL... | E.DKINTAYR | SWLSYNYGN  | PEKGIRSWTL  |
| Penton12  | RIEPVETDPK | GRSYNLL... | P.DKNTKYR  | SWLAYNYGD  | PEKGVRSWTL  |
| Penton40  | EIVPVEKDSK | ERSYNLL... | EGDKNTAYR  | SWFLAYNYGD | AEKGVKSWTL  |
| Penton17  | VIEPIKQDDT | KRSYNLI... | E.GTMDTLR  | SWLSYTYRD  | PENGVSQSWTL |
| Pentonf10 | ...PLLHDSA | GVSYNVIYDQ | VTGKPVTAIR | SWMLAYNVN  | SQANQT..TL  |

451

500

|           |            |            |           |            |             |
|-----------|------------|------------|-----------|------------|-------------|
| Penton5   | LCTPDVTCGS | EQVYWSLPDM | MDPVTFRST | RQISNFPVVG | AELLPVHKS   |
| Penton2   | LCTPDVTCGS | EQVYWSLPDM | MDPVTFRST | RQISNFPVVG | AELLPVHKS   |
| Penton3   | LTTSDVTCGA | EQVYWSLPDM | MDPVTFRST | RQVNNYPVVG | AELMPVFSKS  |
| Penton12  | LTTSDVTCGS | EQVYWSLPDM | MDPVTFRSS | RQVSNYPVVA | AELLPVHAKS  |
| Penton40  | LTTSDVTCGS | EQVYWSLPDM | MDPVTFRPS | TQVSNYPVVG | VELLPVHAKS  |
| Penton17  | LTTSDVTCGA | EQVYWSLPDL | MDPVTFRST | QQVSNYPVVG | AELMPFRAKS  |
| Pentonf10 | LTVPMAGGI  | GAMYTSLPDT | FIAPTGFED | NTTNLCPUVG | MNLFPPTYNKI |

501

550

|          |            |            |            |            |            |
|----------|------------|------------|------------|------------|------------|
| Penton5  | FYNDQAVYSQ | LIRQFT.SLT | HVFNRFPENQ | ILARPPATI  | TTVSENVPAL |
| Penton2  | FYNDQAVYSQ | LIRQFT.SLT | HVFNRFPENQ | ILARPPATI  | TTVSENVPAL |
| Penton3  | FYNEQAVYSQ | QLRQAT.SLT | HVFNRFPENQ | ILIRPPATI  | TTVSENVPAL |
| Penton12 | FYNEQAVYSQ | LIRQST.ALT | HVFNRFPENQ | ILVRPPAATI | TTVSENVPAL |

FIGURE 6B

9/17

Penton40 FYNEQAVYSQ LIRQST.ALT HIFNRFPENQ ILVRPPAPTI TTVSENVFAL  
Penton17 FYNDLAVYSQ LIRSYT.SLT HVFNRFPDNQ ILCRPPAPTI TTVSENVFAL  
Pentonf10 YYQAASTYVQ RLENSCQSAT AAFNRFPENE ILKQAPPMNV SSVCDNQPAV

551

600

Penton5 TDHGTLPRLN SIGGVQRVTI TDARRRTPY VYKALGIVSP RVLSSRTF\*.  
Penton2 TDHGTLPRLN SIGGVQRVTI TDARRRTPY VYKALGIVSP RVLSSRTF\*.  
Penton3 TDHGTLPRLS SIRGVQRVTV TDARRRTPY VYKALGIVAP RVLSSRTF\*.  
Penton12 TDHGTLPRLS SIGGVQRVTI TDARRRTPY VYKALGIVSP RVLSSRTF\*.  
Penton40 TDHGTLPRLS SIGGVQRVTI TDARRRTPY VHKALGIVAP KVLSSRTF\*.  
Penton17 TDHGTLPRLS SIRGVQRVTV TDARRRTPY VYKALGIVAP RVLSSRTF\*.  
Pentonf10 VQQGVLPVKS SLPGLQRVLI TDDQRRPIPY VYKSIATVQP TVLSSATLQ\*

FIGURE 6C







12/17

|           |             |            |            |            |                           |
|-----------|-------------|------------|------------|------------|---------------------------|
|           | 1           |            |            |            | 50                        |
| 8fiber    | MTKRLRA...  | EDDFN      | PVYPYGYARN | Q.NIPFLTPP | FVSSNGFQNF - SEQ ID NO:13 |
| 9fiber    | MSKRLRV...  | EDDFN      | PVYPYGYARN | Q.NIPFLTPP | FVSSDGFQNF - SEQ ID NO:14 |
| 15fiber   | MSKRLRV...  | EDDFN      | PVYPYGYARN | Q.NIPFLTPP | FVSSDGFQNF - SEQ ID NO:15 |
| 17fiber   | MSKRLRV...  | EDDFN      | PVYPYGYARN | Q.NIPFLTPP | FVSSDGFQNF - SEQ ID NO:11 |
| 2fiber    | .MKRARP...  | SEDTFN     | PVYPYDTETG | PPTVPFLTPP | FVSPNGFQES - SEQ ID NO:12 |
| 5fiber    | .MKRARP...  | SEDTFN     | PVYPYDTETG | PPTVPFLTPP | FVSPNGFQES - SEQ ID NO:16 |
| 4fiber    | MSKSARG...  | WSDGFD     | PVYPYDADND | RP.CPSSTLP | SFSSDGFQEK - SEQ ID NO:17 |
| 40-1fiber | .MKRTRIE... | DDFN       | PVYPYD.TSS | TPSIPYVAPP | FVSSDGLQEN - SEQ ID NO:18 |
| 41fiber   | .MKRTRIE... | DDFN       | PVYPYD.TFS | TPSIPYVAPP | FVSSDGLQEK - SEQ ID NO:19 |
| 40-2fiber | .MKRARFE... | DDFN       | PVYPYE.HYN | PLDIPFITPP | FASSNGLOEK - SEQ ID NO:20 |
| 12fiber   | .MKRSRTQYA  | EETEENDDFN | PVYPFD.PFD | TSDVPFVTPP | FTSSNGLOEK - SEQ ID NO:21 |
| 3fiber    | MAKRARL...  | STSFN      | PVYPYEDESS | SOH.PFINPG | FISPDGFTQS - SEQ ID NO:22 |
|           | 51          |            |            |            | 100                       |
| 8fiber    | PPGVLSLKLA  | DPITIN.NQN | VSLKVGGGLT | LQEET..... |                           |
| 9fiber    | PPGVLSLKLA  | DPITIV.NGN | VSLKVGGGLT | LQDGT..... |                           |
| 15fiber   | PPGVLSLKLA  | DPITIA.NGN | VSLKMGGGLT | LQEGT..... |                           |
| 17fiber   | PPGVLSLKLA  | DPITIA.NGD | VSLKVGGGLT | LQE.....   |                           |
| 2fiber    | PPGVLSLRVS  | EPLDTS.HGM | LALKMGSGLT | LDKAGNLTSQ | NVTTVTQPLK                |
| 5fiber    | PPGVLSLRVS  | EPLVTS.NGM | LALKMGNGLS | LDEAGNLTSQ | NVTTVSPPLK                |
| 4fiber    | PLGVLSLPGP  | RPCHTK.NGE | ITLKLGEVD  | LDDSGKLIAN | TVNKAIAPL.                |
| 40-1fiber | PPGVLALKYT  | DPITTNAKHE | LTLKLGSNIT | LQ.NGLLSA. |                           |
| 41fiber   | PPGVLALKYT  | DPITTNAKHE | LTLKLGSNIT | LE.NGLLSA. |                           |
| 40-2fiber | PPGVLSLKYT  | DPLTTK.NGA | LTLKLGTGLN | IDKNGDLSSD | ASVEVSAPIT                |
| 12fiber   | PPGVLALNYK  | DPIVTE.NGT | LTLKLGDGIK | LNAQGQLTAS | NNINVLEPLT                |
| 3fiber    | PNGVLSLKCV  | NPLTTA.SGS | LQLKVGSGLT | VD.....    |                           |
|           | 101         |            |            |            | 150                       |
| 8fiber    | .....       | .....      | .....      | .....      |                           |
| 9fiber    | .....       | .....      | .....      | .....      |                           |
| 15fiber   | .....       | .....      | .....      | .....      |                           |
| 17fiber   | .....       | .....      | .....      | .....      |                           |

FIGURE 8A

13/17

|           |             |             |            |             |            |            |
|-----------|-------------|-------------|------------|-------------|------------|------------|
| 2fiber    | KTKSNISLD   | S           | LTITSGA    | LTVATTAPLI  | VTSGALS    | QAPLTVQDSK |
| 5fiber    | KTKSNINLEI  | SAPLTVTSEA  | LTVAAAAPLM | VAGNTLTMQS  | QAPLTVHDSK |            |
| 4fiber    | .....       | .....       | .....      | ....SFFQQH  | HFPL.....  |            |
| 40-1fiber | .....       | .....       | .....      | .....       | .....      |            |
| 41fiber   | .....       | .....       | .....      | .....       | .....      |            |
| 40-2fiber | KTNKIVGLNY  | TKPLALQNN   | LTLSYNAPFN | VVNNNLALNM  | SQPVTI.... |            |
| 12fiber   | NTSQGLKLSW  | SAPLAVKASA  | LTNTRAPLT  | TTDESLALIT  | APPITVESSR |            |
| 3fiber    | .....       | .....       | .....      | .....       | .....      |            |
|           | 151         |             |            |             | 200        |            |
| 8fiber    | .....       | .....       | .....      | .....       | .....      |            |
| 9fiber    | .....       | .....       | .....      | .....       | .....      |            |
| 15fiber   | .....       | .....       | .....      | .....       | .....      |            |
| 17fiber   | .....       | .....       | .....      | .....       | .....      |            |
| 2fiber    | .....       | .....       | .....      | .....       | LSI        |            |
| 5fiber    | .....       | .....       | .....      | .....       | LSI        |            |
| 4fiber    | .....       | .....       | .....      | .....       | .....      |            |
| 40-1fiber | .....       | .....       | .....      | .....       | .....      |            |
| 41fiber   | .....       | .....       | .....      | .....       | .....      |            |
| 40-2fiber | .....       | NANNELSLL   | IDAPLNADTG | TLRLRSDAPL  | GLVDK.TLKV |            |
| 12fiber   | LGLATTIAPLS | LDGGGNLGLN  | LSAPLDVSNN | NLHLLTTETPL | VVNSSGALS  |            |
| 3fiber    | .....       | .....       | .....      | .....       | .....      |            |
|           | 201         |             |            |             | 250        |            |
| 8fiber    | .....       | .....       | .....GKLT  | VNTEPPLH..  | .....      |            |
| 9fiber    | .....       | .....       | .....GKLT  | VNADPPLQ..  | .....      |            |
| 15fiber   | .....       | .....       | .....GNLT  | VNTEPPLQ..  | .....      |            |
| 17fiber   | .....       | .....       | .....GSLT  | VDPKAPLQ..  | .....      |            |
| 2fiber    | ATKGPITVSD  | GKLALQTSAP  | LSGSDSDTLT | VTASPPLTTA  | TGSLGINMED |            |
| 5fiber    | ATQGPLTVSE  | GKLALQTSAP  | LTTTDSSTLT | ITASPPLTTA  | TGSLGIDLKE |            |
| 4fiber    | .....       | .....TWIP   | LYTPKMENYP | YKFLPPLSIL  | KSTI.....  |            |
| 40-1fiber | .....       | .....TVPT.. | .....      | ..VSPPLTNS  | NNSLGLATSA |            |
| 41fiber   | .....       | .....TVPT.. | .....      | ..VSPPLTNS  | NNSLGLATSA |            |
| 40-2fiber | LFSSPLYLDN  | NFLTALIERP  | LALSSNRAVA | LKYPPLKIE   | NENLTLSTGG |            |
| 12fiber   | ATADPISVRN  | NALTLPATADP | LMVSSD.GLG | ISVTSPITVI  | NGSLALSTTA |            |
| 3fiber    | .....       | .....       | .....      | .....       | .....      |            |
|           | 251         |             |            |             | 300        |            |
| 8fiber    | ..LTNN.KLG  | IALDAPFDVI  | D..NKLTLLA | GHGLSII.TK  | ETSTLPGLVN |            |
| 9fiber    | ..LTNN.KLG  | IALDAPFDVI  | D..NKLTLLA | GHGLSII.TK  | ETSTLPGLRN |            |
| 15fiber   | ..LTNN.RIG  | IALDAPFDVI  | G..GKLTLLA | GHGLSII.TE  | ETSPLPGLVN |            |
| 17fiber   | ..LANNKLE   | LVYVDPFEVS  | A..NKLSLKV | GHGLKILDDK  | SAGGLKDLIG |            |
| 2fiber    | PIYVNNKGIG  | IKISGPLQVA  | QNSDTLTVVT | GPGVTVEQNS  | LRTKVAGAIG |            |
| 5fiber    | PIYTQNGKLG  | LKYGAPLHVT  | DDLNTLTVAT | GPGVTINNTS  | LQTKVTGALG |            |
| 4fiber    | .....       | .....       | ..LNTLVSAF | GSGGLGSGSA  | LAVQLASPLT |            |
| 40-1fiber | PIAVSANSALT | LATAAPLTVS  | N..NQLSINT | GRGLVITNNA  | VAVNPTGALG |            |
| 41fiber   | PIAVSANSALT | LATAAPLTVS  | N..NQLSINA | GRGLVITNNA  | LTVNPTGALG |            |
| 40-2fiber | PFTVSGGNLN  | LATSAPLSVQ  | N..NSLSLGV | NPPFLITDSG  | LAMDLDGDLA |            |
| 12fiber   | PLNSTGSTLS  | LSVANPLTIS  | Q..DTLTVST | GNGLQVSGSQ  | LVTRIGDGLT |            |
| 3fiber    | ...TTDGSLE  | ENIKVNTPLT  | KSNHSINLPI | GNGLQIEQNK  | LCS.....   |            |
|           | 301         |             |            |             | 350        |            |
| 8fiber    | .....       | .....       | .....      | .....       | .....      |            |
| 9fiber    | .....       | .....       | .....      | .....       | .....      |            |
| 15fiber   | .....       | .....       | .....      | .....       | .....      |            |
| 17fiber   | .....       | .....       | .....      | .....       | .....      |            |
| 2fiber    | YDSSNNMEIK  | TGGGMRIN..  | NNLLILDVDY | PFDAQTKLRL  | KLGGQPLYIN |            |

FIGURE 8B

14/17

|           |              |             |             |             |            |            |
|-----------|--------------|-------------|-------------|-------------|------------|------------|
| 5fiber    | FDSQGNMQLN   | /A          | LRIDSQ      | NRRLLILDVSY | PFDAQNQL   | RLGQGPLFIN |
| 4fiber    | FDDKG.....   |             |             |             |            |            |
| 40-1fiber | FNNTGALQLN   | AAGGMRVDGA  | N..LILHVAY  | PFEAINQLTL  | R.....     |            |
| 41fiber   | FNNTGALQLN   | AAGGMRVDGA  | N..LILHVAY  | PFEAINQLTL  | R.....     |            |
| 40-2fiber | LGG.SKLIIN   | LGPGLQMSNG  | A..ITL....  | ALDAALPL..  |            | .....Q     |
| 12fiber   | FDN.GVMKVN   | VAGGMRTSGG  | R..IILDVNY  | PFDASNLSL   | RRGLGLIYNQ |            |
| 3fiber    | .....        |             |             |             |            |            |
|           | 351          |             |             |             |            | 400        |
| 8fiber    | .....        |             |             |             | TLVVLTGKGI |            |
| 9fiber    | .....        |             |             |             | TLVVLTGKGI |            |
| 15fiber   | .....        |             |             |             | TLVVLTGKGL |            |
| 17fiber   | .....        |             |             |             | KLVVLTGKGI |            |
| 2fiber    | ASHNLDINYN   | RGLYLFNASN  | NTKKLEVSIK  | KSSGLNFDNT  | AIAINAGKGL |            |
| 5fiber    | SAHNLDINYN   | KGLYLFNASN  | NSKKLEVNL   | TAKGLMFDAT  | AIAINAGDGL |            |
| 4fiber    | ...NIKITLN   | RGLHVTTGDA  | ....IESNIS  | WAKGIKFEDG  | AIATNIGKGS |            |
| 40-1fiber | .....        |             |             |             |            |            |
| 41fiber   | .....        |             |             |             |            |            |
| 40-2fiber | YKNN.....    |             |             |             | ..QLQLRIGS |            |
| 12fiber   | STNW.....    |             |             |             | ..NLTTDIST |            |
| 3fiber    | .....        |             |             |             |            |            |
|           | 401          |             |             |             |            | 450        |
| 8fiber    | GTDLSNNGG..  | ...NICVRVG  | E.....      | ....GGGLS   | FNDNGDLVAF |            |
| 9fiber    | GTESTDNNGG.. | ...TVCVRVG  | E.....      | ....GGGLS   | FNDNGDLVAF |            |
| 15fiber   | GTDTTDNNGG.. | ...SIRVRVG  | E.....      | ....GGGLS   | FNEAGDLVAF |            |
| 17fiber   | GTEMLQNTDG   | SSRGIGISVR  | A.....      | ....REGLT   | FDNDGYLVAV |            |
| 2fiber    | EFDNTTSESP   | DINPIKTKIG  | SGIDYNENGA  | MITKLGAGLS  | FDNSGAITIG |            |
| 5fiber    | EFG..SPNAP   | NTNPLKTKIG  | HGLEFDSNKA  | MVPKLGAGLS  | FDSTGAITVG |            |
| 4fiber    | RFGTSSTETG   | VNNAYPIQV.. | .....       | ....KLGSGLS | FDSTGAIMAG |            |
| 40-1fiber | .....        | .....LE     | NGLEVTNGGK  | LNVLKGSGLQ  | FDNNGRITIS |            |
| 41fiber   | .....        | .....LE     | NGLEVTSGGK  | LNVLKGSGLQ  | FDSNGRIAIS |            |
| 40-2fiber | ASALIMSGVT   | QTLNVNANTS  | KGLAIENNS.  | LNVKLGNGLR  | FDSWGSIAVS |            |
| 12fiber   | EKGLMFSGN..  | ...QIALNAG  | QGLTFNNGQ.  | LRVKGAGLI   | FDSNNNIALG |            |
| 3fiber    | .....        |             |             | ....KLGNGLT | FDSSNSIALK |            |
|           | 451          |             |             |             |            | 500        |
| 8fiber    | NKKEDK....   | .RTLWTTPDT  | SPNCRID...  | QDKDSKLSLV  | LTKCGSQILA |            |
| 9fiber    | NKKEDK....   | .RTLWTTPDT  | SPNCKID...  | QDKDSKLTIV  | LTKCGSQILA |            |
| 15fiber   | NKKEDM....   | .RTLWTTPDP  | SPNCKII...  | EDKDSKLTII  | LTKCGSQILG |            |
| 17fiber   | NPKYDT....   | .RTLWTTPDT  | SPNCRID...  | KEKDSKLTIV  | LTKCGSQILA |            |
| 2fiber    | NKNDDK....   | .LTLWTTPDP  | SPNCRIH...  | SDNDCKFTLV  | LTKCGSQVLA |            |
| 5fiber    | NKNNDK....   | .LTLWTTPAP  | SPNCRLN...  | AEKDAKLTIV  | LTKCGSQILA |            |
| 4fiber    | NKDYDK....   | .LTLWTTPDP  | SPNCQIL...  | AENDAKLTLC  | LTMCDSQILA |            |
| 40-1fiber | NRIQTRSVTS   | LTTIWSIS.P  | TPNCISIY... | ETQDANLFLC  | LTKNGAHVLG |            |
| 41fiber   | NSNRTRSVPS   | LTTIWSIS.P  | TPNCISIY... | ETQDANLFLC  | LTKNGAHVLG |            |
| 40-2fiber | PTTIT...P.   | .TTLWTTPADP | SPNATFY...  | ESLDAKVWLV  | LVKCNGMVNG |            |
| 12fiber   | SSSNTFYDP.   | .LTLWTTPDP  | PPNCSLI...  | QELDAKLTLC  | LTKNGSIVNG |            |
| 3fiber    | NN.....      | ..TLWTGPKP  | EANCIIEYK   | QNPDSKLTII  | LVKNGGIYNG |            |
|           | 501          |             |             |             |            | 550        |
| 8fiber    | NVSLIVVAGR   | YKIINNNTNP  | ..ALKGFTIK  | LLFDKNGVLM  | ESSN.....  |            |
| 9fiber    | NVSLIVVDGK   | YKIINNNTQP  | ..ALKGFTIK  | LLFDENGVLN  | ESSN.....  |            |
| 15fiber   | SVSLIVVVGK   | FSNINNNTNP  | NEADKQITVK  | LLFDANGVLK  | QGST.....  |            |
| 17fiber   | NVSLIVVSGK   | YQYIDHATNP  | ..TLKSFKIK  | LLFDNKGVLN  | PSSN.....  |            |
| 2fiber    | TVAALAV.S.   | ....GDLSSM  | TGTVASVSIF  | LRFDQNGVLM  | ENSS.....  |            |
| 5fiber    | TVSVLAV.K.   | ....GSLAPI  | SGTVQSAHLI  | IRFDENGVLN  | NNSF.....  |            |

FIGURE 8C

15/17

|           |            |            |            |            |            |           |
|-----------|------------|------------|------------|------------|------------|-----------|
| 4fiber    | TVSVLVVRS. | ..         | GNLNPI     | TGTVSSAQVF | LRFDANGV   | TEHS..... |
| 40-1fiber | TITIKGLKGA | LREMNDNA.. | .....LSVK  | LPFDNQGNLL | NCA.....   |           |
| 41fiber   | TITIKGLKGA | LREMNDNA.. | .....LSLK  | LPFDNQGNLL | NCA.....   |           |
| 40-2fiber | TISIKAQKGT | LL..KPTASF | .....ISFV  | MYFYSDGTWR | KNYPVFDNEG |           |
| 12fiber   | IVSLVGKGN  | LLNIQSTTTT | .....VGVH  | LVFDEQGRLI | TSTP.....T |           |
| 3fiber    | YVTLMGASDY | VNTLFKNKNV | .....SINVE | LYFDATGHIL | PDSSSLKTDL |           |
| 551       |            |            |            |            |            |           |
| 8fiber    | ..LGKSYWNF | RNQNSIMSTA | YEKAIGFMPN | LVAYPKPTTG | SKKY...ARD |           |
| 9fiber    | ..LGKSYWNF | RNENSIMSTA | YEKAIGFMPN | LVAYPKPTAG | SKKY...ARD |           |
| 15fiber   | ..MDSSYWNY | RSDNSNLSQP | YKKAUGFMPN | KTAYPKQTKP | TNKEISQAKN |           |
| 17fiber   | ..LDSTYWNF | RSDNLTVSEA | YKNAVEFMPN | LVAYPKPTTG | SKKY...ARD |           |
| 2fiber    | ..LKKHYWNF | RNGNSTNANP | YTNAUGFMPN | LLAYPKTQSO | T.....AKN  |           |
| 5fiber    | ..LDPEYWNF | RNGDLTEGTA | YTNAUGFMPN | LSAYPKSHGK | T.....AKS  |           |
| 4fiber    | ..TSKKYWGY | KQGDSIDGTP | YTNAUGFMPN | STAYPKTQSS | T.....TKN  |           |
| 40-1fiber | ..LESSTWRY | QETNAVA... | .SNALTFMPN | STVYPRNKTA | D.....PGN  |           |
| 41fiber   | ..LESSTWRY | QETNAVA... | .SNALTFMPN | STVYPRNKTA | H.....PGN  |           |
| 40-2fiber | ILANSATWGY | RQGQSANTN  | VSNAVEFMPN | SKRYPNKGS  | E.....VON  |           |
| 12fiber   | ALVPOASWGY | RQGQSVSTNT | VTNGLGFMPN | VSAYPRPNAS | E.....AKS  |           |
| 3fiber    | ELKYQTADF  | .....      | ..SARGFMPS | TTAYPFVLPN | AGTH...NEN |           |
| 601       |            |            |            |            |            |           |
| 8fiber    | IVYGNILGG  | KPHQ..PVTI | KTTFNQETG. | .....CEYS  | ITFDFSWAKT |           |
| 9fiber    | IVYGNILGG  | KPDQ..PVTI | KTTFNQETG. | .....CEYS  | ITFDFSWAKT |           |
| 15fiber   | KIVSNVYLGG | KIDQ..PCVI | IISFNNEAD. | .....SDYS  | IVFYFKWYKT |           |
| 17fiber   | IVYGNILGG  | LAYQ..PVVI | KVTFNEEAD. | .....SAYS  | ITFEFVNKE  |           |
| 2fiber    | NIVSQVYLHG | DKTK..PML  | TITLNGTSES | TETSEVSTYS | MSFTWSWESG |           |
| 5fiber    | NIVSQVYLHG | DKTK..PVTI | TITLNGTQET | GDTT.PSAYS | MSFSWDWSGH |           |
| 4fiber    | NIVGQVYMNG | DVSK..PMLL | TITLNGTDDT | T.....SAYS | MSFSYTWING |           |
| 40-1fiber | MLI.....   | QISP..NITF | SVVYNEINS. | .....GYA   | FTFKW.SAEP |           |
| 41fiber   | MLI.....   | QISP..NITF | SVVYNEINS. | .....GYA   | FTFKW.SAEP |           |
| 40-2fiber | MALTYTFLQG | DPNM..AISF | OSIYN..HA. | .....IEGYS | LKFTW.RVRN |           |
| 12fiber   | QMVSLTYLQG | DTSK..PITM | KVAFNGITS. | .....LNGYS | LTFMW.SGLS |           |
| 3fiber    | YIFGQCYKA  | SDGALFPLEV | TVMLNKRLPD | SRTSYVMTFL | WSLNAGLAPE |           |
| 651       |            |            |            |            |            |           |
| 8fiber    | .YVNVEFETT | SFTFSYIAQE | ..         |            |            |           |
| 9fiber    | .YVNVEFETT | SFTFSYIAQE | ..         |            |            |           |
| 15fiber   | .YENVQFDSS | SFNFSYIAQE | ..         |            |            |           |
| 17fiber   | .YARVEFETT | SFTFSYIAQQ | ..         |            |            |           |
| 2fiber    | KYTTETFATN | SYTFSYIAQE | ..         |            |            |           |
| 5fiber    | NYINEIFATS | SYTFSYIAQE | ..         |            |            |           |
| 4fiber    | SYIGATFGAN | SYTFSYIAQQ | ..         |            |            |           |
| 40-1fiber | ...GKPFHPP | TAVFCYITEQ | ..         |            |            |           |
| 41fiber   | ...GKPFHPP | TAVFCYITEQ | ..         |            |            |           |
| 40-2fiber | ...NERFDIP | CCSFSYVTEQ | ..         |            |            |           |
| 12fiber   | NYINQPFSTP | SCSFSYITOE | ..         |            |            |           |
| 3fiber    | T.TQATLITS | PFTFSYIRED | D.         |            |            |           |
| 672       |            |            |            |            |            |           |

FIGURE 8D

16/17





FIGURE 9

17/17

# Cancer Cell Lines



EXAMPLE 10

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 97/21494

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 C12N15/86 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C12N A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|------------|---|-----------------------|
| A          | P.W. ROELVINK ET AL.: "Comparative analysis of adenovirus fiber-cell interaction: Ad2 and Ad9 utilize the same cellular fiber receptor but use different binding strategies for attachment" JOURNAL OF VIROLOGY, vol. 70, no. 11, November 1996, AMERICAN SOCIETY FOR MICROBIOLOGY US, pages 7614-7621, XP002062100 see page 7620, last paragraph | 1-13                  |
| A          | WO 96 26281 A (GENVEC INC ; CORNELL RES FOUNDATION INC (US)) 29 August 1996 see example 7<br>---<br>-/-   | 1,4,6-8, 10,11        |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

14 April 1998

Date of mailing of the international search report

123.04.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Cupido, M



# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 97/21494

**C.(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT**

| Category * | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|------------|--|-----------------------|
| A          | J. GALL ET AL: "Adenovirus type 5 and 7 capsid chimera: Fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes"<br>JOURNAL OF VIROLOGY.,<br>vol. 70, no. 4, April 1996,<br>pages 2116-2123, XP002050655<br>see the whole document<br>----- | 1,4,6-8,<br>10,11     |
| P,X        | WO 97 12986 A (CORNELL RES FOUNDATION INC)<br>10 April 1997<br>see page 15, line 1 - line 7<br>-----   | 1,2,13                |

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 97/ 21494

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 11 to 13  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although these claims are directed to a method of treatment of the human or animal body, the search has been carried out and based on the alleged effects of the adenoviral vector
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No  
PCT/US 97/21494

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s)                   | Publication<br>date              |
|---|---------------------|--|----------------------------------|
| WO 9626281 A                              | 29-08-96            | AU 4980496 A<br>CA 2213343 A<br>EP 0811069 A | 11-09-96<br>29-08-96<br>10-12-97 |
| -----                                     | -----               | -----  | -----                            |
| WO 9712986 A                              | 10-04-97            | NONE   |                                  |
| -----                                     | -----               | -----  | -----                            |